

(12) **United States Patent**
Jaeb et al.

(10) **Patent No.:** **US 12,097,094 B2**
(45) **Date of Patent:** ***Sep. 24, 2024**

(54) **DRESSING AND METHOD FOR APPLYING REDUCED PRESSURE TO AND COLLECTING AND STORING FLUID FROM A TISSUE SITE**

(71) Applicant: **Solvantum Intellectual Properties Company**, Maplewood, MN (US)

(72) Inventors: **Jonathan Paul Jaeb**, Boerne, TX (US); **Richard Daniel John Coulthard**, Verwood (GB); **Timothy Mark Robinson**, Shillingstone (GB); **Christopher Brian Locke**, Bournemouth (GB); **Aidan Marcus Tout**, Alderbury (GB)

(73) Assignee: **Solvantum Intellectual Properties Company**, Maplewood, MN (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 472 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **17/242,746**

(22) Filed: **Apr. 28, 2021**

(65) **Prior Publication Data**
US 2021/0244874 A1 Aug. 12, 2021

Related U.S. Application Data

(60) Continuation of application No. 15/944,639, filed on Apr. 3, 2018, now Pat. No. 11,020,516, which is a (Continued)

(51) **Int. Cl.**
A61F 13/05 (2024.01)
A61F 13/00 (2006.01)
A61M 1/00 (2006.01)

(52) **U.S. Cl.**
CPC **A61F 13/05** (2024.01); **A61F 13/00063** (2013.01); **A61M 1/74** (2021.05); (Continued)

(58) **Field of Classification Search**
CPC **A61F 13/00068**; **A61F 2013/00174**; **A61F 2013/0017**; **A61M 1/74**; **A61M 1/915**; (Continued)

(56) **References Cited**
U.S. PATENT DOCUMENTS

1,355,846 A 10/1920 Rannells
1,944,834 A 1/1934 Bennett
(Continued)

FOREIGN PATENT DOCUMENTS

AU 550575 B2 3/1986
AU 745271 B2 3/2002
(Continued)

OTHER PUBLICATIONS

Louis C. Argenta, MD and Michael J. Morykwas, PHD; Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience; Annals of Plastic Surgery; vol. 38, No. 6, Jun. 1997; pp. 563-576.


(Continued)

Primary Examiner — Susan S Su

(57) **ABSTRACT**

A reduced pressure dressing for applying reduced pressure treatment to a tissue site includes an interface layer adapted to be positioned at the tissue site. An absorbent layer is in fluid communication with the interface layer to absorb liquid from at least one of the interface layer and the tissue site. A pump is in fluid communication with the absorbent layer to deliver a reduced pressure to the tissue site. A cover is positioned over the pump, the absorbent layer, and the interface layer to maintain the reduced pressure at the tissue site, and a liquid-air separator is positioned between the

(Continued)



absorbent layer and the pump to inhibit liquid from entering the pump.

17 Claims, 16 Drawing Sheets

Related U.S. Application Data

continuation of application No. 14/703,667, filed on May 4, 2015, now Pat. No. 10,010,656, which is a division of application No. 13/709,255, filed on Dec. 10, 2012, now Pat. No. 9,050,209, which is a continuation of application No. 12/398,904, filed on Mar. 5, 2009, now Pat. No. 8,372,050.

(60) Provisional application No. 61/049,028, filed on Apr. 30, 2008, provisional application No. 61/034,013, filed on Mar. 5, 2008.

(52) **U.S. Cl.**

CPC *A61M 1/78* (2021.05); *A61M 1/784* (2021.05); *A61M 1/915* (2021.05); *A61M 1/962* (2021.05); *A61M 1/985* (2021.05); *A61F 2013/00174* (2013.01); *A61F 2013/00412* (2013.01); *A61F 2013/00536* (2013.01); *A61F 2013/00544* (2013.01); *A61M 1/912* (2021.05); *A61M 1/964* (2021.05); *A61M 1/966* (2021.05); *A61M 2205/15* (2013.01); *A61M 2205/7536* (2013.01)

(58) **Field of Classification Search**

CPC *A61M 1/962*; *A61M 2205/7536*; *A61M 1/009*

See application file for complete search history.

(56)

References Cited

U.S. PATENT DOCUMENTS

2,399,545 A 4/1946 Davis
 2,547,758 A 4/1951 Keeling
 2,552,664 A 5/1951 Burdine
 2,632,443 A 3/1953 Leshner
 2,682,873 A 7/1954 Evans et al.
 2,860,081 A 11/1958 Eiken
 2,910,763 A 11/1959 Lauterbach
 2,969,057 A 1/1961 Simmons
 3,066,672 A 12/1962 Crosby, Jr. et al.
 3,122,140 A 2/1964 Crowe, Jr.
 3,172,808 A 3/1965 Baumann et al.
 3,183,116 A 5/1965 Schaar
 3,214,502 A 10/1965 Schaar
 3,367,332 A 2/1968 Groves
 3,376,868 A 4/1968 Mondiadis
 3,515,270 A 6/1970 Yang et al.
 3,520,300 A 7/1970 Flower, Jr.
 3,568,675 A 3/1971 Harvey
 3,645,835 A 2/1972 Hodgson
 3,648,692 A 3/1972 Wheeler
 3,682,180 A 8/1972 McFarlane
 3,742,952 A 7/1973 Magers et al.
 3,762,415 A 10/1973 Morrison
 3,774,611 A 11/1973 Tussey et al.
 3,777,016 A 12/1973 Gilbert
 3,779,243 A 12/1973 Tussey et al.
 3,811,438 A 5/1974 Economou
 3,826,254 A 7/1974 Mellor
 3,852,823 A 12/1974 Jones
 3,903,882 A 9/1975 Augurt
 3,967,624 A 7/1976 Milnamow
 3,983,297 A 9/1976 Ono et al.
 4,060,081 A 11/1977 Yannas et al.
 4,080,970 A 3/1978 Miller

4,096,853 A 6/1978 Weigand
 4,139,004 A 2/1979 Gonzalez, Jr.
 4,141,361 A 2/1979 Snyder
 4,163,822 A 8/1979 Walter
 4,165,748 A 8/1979 Johnson
 4,174,664 A 11/1979 Arnott et al.
 4,184,510 A 1/1980 Murry et al.
 4,233,969 A 11/1980 Lock et al.
 4,245,630 A 1/1981 Lloyd et al.
 4,256,109 A 3/1981 Nichols
 4,261,363 A 4/1981 Russo
 4,275,721 A 6/1981 Olson
 4,284,079 A 8/1981 Adair
 4,297,995 A 11/1981 Golub
 4,323,069 A 4/1982 Ahr et al.
 4,333,468 A 6/1982 Geist
 4,343,848 A 8/1982 Leonard, Jr.
 4,360,015 A 11/1982 Mayer
 4,373,519 A 2/1983 Errede et al.
 4,382,441 A 5/1983 Svedman
 4,392,853 A 7/1983 Muto
 4,392,858 A 7/1983 George et al.
 4,414,970 A 11/1983 Berry
 4,419,097 A 12/1983 Rowland
 4,465,485 A 8/1984 Kashmer et al.
 4,475,909 A 10/1984 Eisenberg
 4,480,638 A 11/1984 Schmid
 4,525,166 A 6/1985 Leclerc
 4,525,374 A 6/1985 Vaillancourt
 4,529,402 A 7/1985 Weilbacher et al.
 4,540,412 A 9/1985 Van Overloop
 4,543,100 A 9/1985 Brodsky
 4,548,202 A 10/1985 Duncan
 4,551,139 A 11/1985 Plaas et al.
 4,569,348 A 2/1986 Hasslinger
 4,600,146 A 7/1986 Ohno
 4,605,399 A 8/1986 Weston et al.
 4,608,041 A 8/1986 Nielsen
 4,617,021 A 10/1986 Leuprecht
 4,640,688 A 2/1987 Hauser
 4,655,754 A 4/1987 Richmond et al.
 4,664,652 A 5/1987 Weilbacher
 4,664,662 A 5/1987 Webster
 4,705,543 A 11/1987 Kertzman
 4,710,165 A 12/1987 McNeil et al.
 4,715,857 A 12/1987 Juhasz et al.
 4,733,659 A 3/1988 Edenbaum et al.
 4,743,232 A 5/1988 Kruger
 4,753,230 A 6/1988 Carus et al.
 4,758,220 A 7/1988 Sundblom et al.
 4,773,408 A 9/1988 Cilentio et al.
 4,787,888 A 11/1988 Fox
 4,826,494 A 5/1989 Richmond et al.
 4,832,008 A 5/1989 Gilman
 4,838,883 A 6/1989 Matsuura
 4,840,187 A 6/1989 Brazier
 4,842,594 A 6/1989 Ness
 4,848,364 A 7/1989 Bosman
 4,863,449 A 9/1989 Therriault et al.
 4,871,611 A 10/1989 LeBel
 4,872,450 A 10/1989 Austad
 4,878,901 A 11/1989 Sachse
 4,897,081 A 1/1990 Poirier et al.
 4,906,233 A 3/1990 Moriuchi et al.
 4,906,240 A 3/1990 Reed et al.
 4,919,654 A 4/1990 Kalt
 4,930,997 A 6/1990 Bennett
 4,935,005 A 6/1990 Haines
 4,941,882 A 7/1990 Ward et al.
 4,953,565 A 9/1990 Tachibana et al.
 4,961,493 A 10/1990 Kaihatsu
 4,969,880 A 11/1990 Zamierowski
 4,981,474 A 1/1991 Bopp et al.
 4,985,019 A 1/1991 Michelson
 4,995,382 A 2/1991 Lang et al.
 4,996,128 A 2/1991 Aldecoa et al.
 5,010,883 A 4/1991 Rawlings et al.
 5,018,515 A 5/1991 Gilman
 5,025,783 A 6/1991 Amb

(56)

References Cited

U.S. PATENT DOCUMENTS

5,028,597	A	7/1991	Kodama et al.	6,086,995	A	7/2000	Smith
5,037,397	A	8/1991	Kalt et al.	6,135,116	A	10/2000	Vogel et al.
5,042,500	A	8/1991	Norlien et al.	6,159,877	A	12/2000	Scholz et al.
5,086,170	A	2/1992	Luheshi et al.	6,174,306	B1	1/2001	Fleischmann
5,092,323	A	3/1992	Riedel et al.	6,191,335	B1	2/2001	Robinson
5,092,858	A	3/1992	Benson et al.	6,201,164	B1	3/2001	Wulff et al.
5,100,396	A	3/1992	Zamierowski	6,228,485	B1	5/2001	Leiter
5,112,323	A	5/1992	Winkler et al.	6,238,762	B1	5/2001	Friedland et al.
5,127,601	A	7/1992	Schroeder	6,241,747	B1	6/2001	Ruff
5,134,994	A	8/1992	Say	6,262,329	B1	7/2001	Brunsveld et al.
5,149,331	A	9/1992	Ferdman et al.	6,287,316	B1	9/2001	Agarwal et al.
5,151,314	A	9/1992	Brown	6,345,623	B1	2/2002	Heaton et al.
5,152,757	A	10/1992	Eriksson	6,457,200	B1	10/2002	Tanaka et al.
5,167,613	A	12/1992	Karami et al.	6,458,109	B1	10/2002	Henley et al.
5,176,663	A	1/1993	Svedman et al.	6,488,643	B1	12/2002	Tumey et al.
5,180,375	A	1/1993	Feibus	6,493,568	B1	12/2002	Bell et al.
5,215,522	A	6/1993	Page et al.	6,495,229	B1	12/2002	Carte et al.
5,232,453	A	8/1993	Plass et al.	6,503,855	B1	1/2003	Menzies et al.
5,244,457	A	9/1993	Karami et al.	6,548,727	B1	4/2003	Swenson
5,246,775	A	9/1993	Loscuito	6,553,998	B2	4/2003	Heaton et al.
5,261,893	A	11/1993	Zamierowski	6,566,575	B1	5/2003	Stickels et al.
5,266,372	A	11/1993	Arakawa et al.	6,566,577	B1	5/2003	Addison et al.
5,270,358	A	12/1993	Asmus	6,626,891	B2	9/2003	Ohmstede
5,271,987	A	12/1993	Iskra	6,627,215	B1	9/2003	Dale et al.
5,278,100	A	1/1994	Doan et al.	6,648,862	B2	11/2003	Watson
5,279,550	A	1/1994	Habib et al.	6,680,113	B1	1/2004	Lucast et al.
5,298,015	A	3/1994	Komatsuzaki et al.	6,685,681	B2	2/2004	Lockwood et al.
5,342,329	A	8/1994	Croquevielle	6,693,180	B2	2/2004	Lee et al.
5,342,376	A	8/1994	Ruff	6,695,823	B1	2/2004	Lina et al.
5,344,415	A	9/1994	DeBusk et al.	6,752,794	B2	6/2004	Lockwood et al.
5,356,386	A	10/1994	Goldberg et al.	6,787,682	B2	9/2004	Gilman
5,358,494	A	10/1994	Svedman	6,806,214	B2	10/2004	Li et al.
5,384,174	A	1/1995	Ward et al.	6,814,079	B2	11/2004	Heaton et al.
5,387,207	A	2/1995	Dyer et al.	6,855,135	B2	2/2005	Lockwood et al.
5,419,769	A	5/1995	Devlin et al.	6,856,821	B2	2/2005	Johnson
5,423,778	A	6/1995	Eriksson et al.	6,979,324	B2	12/2005	Bybordi et al.
5,429,590	A	7/1995	Saito et al.	7,070,584	B2	7/2006	Johnson et al.
5,437,622	A	8/1995	Carion	7,154,017	B2	12/2006	Sigurjonsson et al.
5,437,651	A	8/1995	Todd et al.	7,402,721	B2	7/2008	Sigurjonsson et al.
5,445,604	A	8/1995	Lang	7,569,742	B2	8/2009	Haggstrom et al.
5,447,492	A	9/1995	Cartmell et al.	7,645,269	B2	1/2010	Zamierowski
5,458,938	A	10/1995	Nygaard et al.	7,846,141	B2	12/2010	Weston
5,501,212	A	3/1996	Psaros	8,062,273	B2	11/2011	Weston
5,522,808	A	6/1996	Skalla	8,216,198	B2	7/2012	Heagle et al.
5,527,293	A	6/1996	Zamierowski	8,251,979	B2	8/2012	Malhi
5,549,584	A	8/1996	Gross	8,257,327	B2	9/2012	Blott et al.
5,549,585	A	8/1996	Maher et al.	8,298,197	B2	10/2012	Eriksson et al.
5,556,375	A	9/1996	Ewall	8,398,614	B2	3/2013	Blott et al.
5,585,178	A	12/1996	Calhoun et al.	8,449,509	B2	5/2013	Weston
5,599,292	A	2/1997	Yoon	8,529,532	B2	9/2013	Pinto et al.
5,607,388	A	3/1997	Ewall	8,529,548	B2	9/2013	Blott et al.
5,611,373	A	3/1997	Ashcraft	8,535,296	B2	9/2013	Blott et al.
5,634,893	A	6/1997	Rishton	8,551,060	B2	10/2013	Schuessler et al.
5,636,643	A	6/1997	Argenta et al.	8,568,386	B2	10/2013	Malhi
5,641,506	A	6/1997	Talke et al.	8,632,523	B2	1/2014	Eriksson et al.
5,645,081	A	7/1997	Argenta et al.	8,679,081	B2	3/2014	Heagle et al.
5,653,224	A	8/1997	Johnson	8,764,732	B2	7/2014	Hartwell
5,678,564	A	10/1997	Lawrence et al.	8,834,451	B2	9/2014	Blott et al.
5,710,233	A	* 1/1998	Meckel C08G 18/65 525/173	8,920,830	B2	12/2014	Mathies
5,714,225	A	2/1998	Hansen et al.	8,926,592	B2	1/2015	Blott et al.
5,736,470	A	4/1998	Schneberger et al.	9,017,302	B2	4/2015	Vitaris et al.
5,759,570	A	6/1998	Arnold	9,192,444	B2	11/2015	Locke et al.
5,776,119	A	7/1998	Bilbo et al.	9,198,801	B2	12/2015	Weston
5,807,295	A	9/1998	Hutcheon et al.	9,211,365	B2	12/2015	Weston
5,830,201	A	11/1998	George et al.	9,289,542	B2	3/2016	Blott et al.
5,878,971	A	3/1999	Minnema	9,572,719	B2	2/2017	Long et al.
5,902,439	A	5/1999	Pike et al.	9,877,873	B2	1/2018	Coulthard et al.
5,919,476	A	7/1999	Fischer et al.	9,956,120	B2	5/2018	Locke
5,941,863	A	8/1999	Guidotti et al.	10,940,047	B2	3/2021	Locke et al.
5,964,252	A	10/1999	Simmons et al.	2001/0030304	A1	10/2001	Kohda et al.
5,981,822	A	11/1999	Addison	2001/0051178	A1	12/2001	Blatchford et al.
5,998,561	A	12/1999	Jada	2002/0009568	A1	1/2002	Bries et al.
6,071,267	A	6/2000	Zamierowski	2002/0016346	A1	2/2002	Brandt et al.
6,083,616	A	7/2000	Dressler	2002/0065494	A1	5/2002	Lockwood et al.
				2002/0077661	A1	6/2002	Saadat
				2002/0090496	A1	7/2002	Kim et al.
				2002/0115951	A1	8/2002	Norstrem et al.
				2002/0119292	A1	8/2002	Venkatasanthanam et al.
				2002/0120185	A1	8/2002	Johnson

(56)		References Cited						
U.S. PATENT DOCUMENTS								
2002/0130064	A1	9/2002	Adams et al.		2007/0265586	A1	11/2007	Joshi et al.
2002/0143286	A1	10/2002	Tumey		2007/0283962	A1	12/2007	Doshi et al.
2002/0150270	A1	10/2002	Werner		2008/0009812	A1	1/2008	Riesinger
2002/0150720	A1	10/2002	Howard et al.		2008/0027366	A1	1/2008	Da Silva Macedo
2002/0161346	A1	10/2002	Lockwood et al.		2008/0082059	A1	4/2008	Fink et al.
2002/0164346	A1	11/2002	Nicolette		2008/0090085	A1	4/2008	Kawate et al.
2002/0183702	A1	12/2002	Henley et al.		2008/0095979	A1	4/2008	Hatanaka et al.
2002/0198504	A1	12/2002	Risk et al.		2008/0119802	A1	5/2008	Riesinger
2003/0014022	A1*	1/2003	Lockwood	A61M 1/732 604/315	2008/0138591	A1	6/2008	Graham et al.
2003/0070680	A1	4/2003	Smith et al.		2008/0149104	A1	6/2008	Eifler
2003/0109855	A1	6/2003	Solem et al.		2008/0173389	A1	7/2008	Mehta et al.
2003/0158577	A1	8/2003	Ginn et al.		2008/0195017	A1	8/2008	Robinson et al.
2003/0208175	A1	11/2003	Gross et al.		2008/0225663	A1	9/2008	Smith et al.
2003/0212357	A1	11/2003	Pace		2008/0243044	A1	10/2008	Hunt et al.
2003/0225347	A1	12/2003	Argenta et al.		2008/0269657	A1	10/2008	Brenneman et al.
2003/0225355	A1	12/2003	Butler		2008/0271804	A1	11/2008	Biggie et al.
2004/0002676	A1	1/2004	Sieglwart et al.		2009/0025724	A1	1/2009	Herron, Jr.
2004/0030304	A1*	2/2004	Hunt	A61F 13/00068 604/317	2009/0088719	A1	4/2009	Driskell
2004/0064132	A1	4/2004	Boehringer et al.		2009/0093779	A1	4/2009	Riesinger
2004/0077984	A1	4/2004	Worthley		2009/0124988	A1	5/2009	Coulthard
2004/0082925	A1	4/2004	Patel		2009/0177172	A1	7/2009	Wilkes
2004/0099268	A1	5/2004	Smith et al.		2009/0216168	A1	8/2009	Eckstein
2004/0118401	A1	6/2004	Smith et al.		2009/0216170	A1	8/2009	Robinson et al.
2004/0127836	A1	7/2004	Sigurjonsson et al.		2009/0216204	A1	8/2009	Bhavaraju et al.
2004/0127862	A1	7/2004	Bubb et al.		2009/0227968	A1	9/2009	Vess
2004/0133143	A1	7/2004	Burton et al.		2009/0227969	A1	9/2009	Jaeb et al.
2004/0163278	A1	8/2004	Caspers et al.		2009/0234306	A1	9/2009	Vitaris
2004/0186239	A1	9/2004	Qin et al.		2009/0234307	A1	9/2009	Vitaris
2004/0219337	A1	11/2004	Langley et al.		2009/0264807	A1	10/2009	Haggstrom et al.
2004/0230179	A1	11/2004	Shehada		2009/0292264	A1	11/2009	Hudspeth et al.
2004/0241214	A1	12/2004	Kirkwood et al.		2009/0299251	A1	12/2009	Buan
2005/0034731	A1	2/2005	Rousseau et al.		2009/0312662	A1	12/2009	Colman et al.
2005/0054998	A1	3/2005	Poccia et al.		2009/0326487	A1	12/2009	Vitaris
2005/0058810	A1	3/2005	Dodge et al.		2009/0326488	A1	12/2009	Budig et al.
2005/0059918	A1	3/2005	Sigurjonsson et al.		2010/0028390	A1	2/2010	Cleary et al.
2005/0065484	A1	3/2005	Watson		2010/0030170	A1	2/2010	Keller et al.
2005/0070858	A1	3/2005	Lockwood et al.		2010/0030178	A1	2/2010	MacMeccan et al.
2005/0101940	A1	5/2005	Radl et al.		2010/0063467	A1	3/2010	Addison et al.
2005/0113732	A1	5/2005	Lawry		2010/0069863	A1	3/2010	Olson
2005/0124925	A1	6/2005	Scherpenborg		2010/0106106	A1	4/2010	Heaton et al.
2005/0131327	A1	6/2005	Lockwood et al.		2010/0106118	A1	4/2010	Heaton et al.
2005/0137539	A1	6/2005	Biggie et al.		2010/0111919	A1	5/2010	Abuzaina et al.
2005/0143694	A1	6/2005	Schmidt et al.		2010/0125259	A1	5/2010	Olson
2005/0158442	A1	7/2005	Westermann et al.		2010/0159192	A1	6/2010	Cotton
2005/0159695	A1	7/2005	Cullen et al.		2010/0168633	A1	7/2010	Bougherara et al.
2005/0161042	A1	7/2005	Fudge et al.		2010/0168635	A1	7/2010	Freiding et al.
2005/0163978	A1	7/2005	Strobech et al.		2010/0185163	A1	7/2010	Heagle
2005/0214376	A1	9/2005	Faure et al.		2010/0191197	A1	7/2010	Braga et al.
2005/0233072	A1	10/2005	Stephan et al.		2010/0212768	A1	8/2010	Resendes
2005/0256437	A1	11/2005	Silcock et al.		2010/0226824	A1	9/2010	Ophir et al.
2005/0261642	A1	11/2005	Weston		2010/0262090	A1	10/2010	Riesinger
2005/0261643	A1	11/2005	Bybordt et al.		2010/0267302	A1	10/2010	Kantner et al.
2005/0277860	A1	12/2005	Jensen		2010/0268144	A1	10/2010	Lu et al.
2005/0283105	A1	12/2005	Heaton et al.		2010/0286582	A1	11/2010	Simpson et al.
2006/0014030	A1	1/2006	Langen et al.		2010/0305490	A1	12/2010	Coulthard et al.
2006/0020235	A1	1/2006	Siniaguine		2010/0305524	A1	12/2010	Vess et al.
2006/0079852	A1	4/2006	Bubb et al.		2010/0312159	A1	12/2010	Aali et al.
2006/0083776	A1	4/2006	Bott et al.		2010/0318072	A1	12/2010	Johnston et al.
2006/0154546	A1	7/2006	Murphy et al.		2010/0324516	A1	12/2010	Braga et al.
2006/0236979	A1	10/2006	Stolarz et al.		2011/0046585	A1	2/2011	Weston
2006/0241542	A1	10/2006	Gudnason et al.		2011/0054423	A1	3/2011	Blott et al.
2006/0271020	A1*	11/2006	Huang	F04B 23/02 604/890.1	2011/0118683	A1	5/2011	Weston
2007/0027414	A1	2/2007	Hoffman et al.		2011/0137271	A1	6/2011	Andresen et al.
2007/0028526	A1	2/2007	Woo et al.		2011/0160686	A1	6/2011	Ueda et al.
2007/0078366	A1*	4/2007	Haggstrom	A61M 27/00 602/53	2011/0171480	A1	7/2011	Mori et al.
2007/0135787	A1	6/2007	Raidel et al.		2011/0172617	A1	7/2011	Riesinger
2007/0161937	A1	7/2007	Aali		2011/0201984	A1	8/2011	Dubrow et al.
2007/0185426	A1	8/2007	Ambrosio et al.		2011/0224631	A1	9/2011	Simmons et al.
2007/0190281	A1	8/2007	Hooff		2011/0229688	A1	9/2011	Cotton
2007/0225663	A1	9/2007	Watt et al.		2011/0237969	A1	9/2011	Eckerbom et al.
2007/0265585	A1	11/2007	Joshi et al.		2011/0244010	A1	10/2011	Doshi
					2011/0257612	A1	10/2011	Locke et al.
					2011/0257617	A1	10/2011	Franklin
					2011/0280926	A1	11/2011	Junginger
					2011/0281084	A1	11/2011	Ashwell
					2011/0282309	A1	11/2011	Adie et al.
					2012/0016322	A1	1/2012	Coulthard et al.
					2012/0019031	A1	1/2012	Bessert
					2012/0036733	A1	2/2012	Dehn

(56)	References Cited			EP	0538917	A1	4/1993
	U.S. PATENT DOCUMENTS			EP	0630629	A1	12/1994
				EP	0659390	A2	6/1995
				EP	0633758	B1	10/1996
2012/0040131	A1	2/2012	Speer	EP	1002846	A1	5/2000
2012/0059339	A1	3/2012	Gundersen	EP	1018967	A1	7/2000
2012/0095380	A1	4/2012	Gergely et al.	EP	2578193	A1	4/2013
2012/0109034	A1	5/2012	Locke et al.	GB	692578	A	6/1953
2012/0123359	A1	5/2012	Reed	GB	1386800	A	3/1975
2012/0143157	A1	6/2012	Riesinger	GB	2195255	A	4/1988
2012/0237722	A1	9/2012	Seyler et al.	GB	2 197 789	A	6/1988
2012/0258271	A1	10/2012	Maughan	GB	2205243	A	12/1988
2012/0310186	A1	12/2012	Moghe et al.	GB	2 220 357	A	1/1990
2013/0030394	A1	1/2013	Locke et al.	GB	2 235 877	A	3/1991
2013/0053746	A1	2/2013	Roland et al.	GB	2 329 127	A	3/1999
2013/0066285	A1	3/2013	Locke et al.	GB	2 333 965	A	8/1999
2013/0096518	A1	4/2013	Hall et al.	GB	2377939	A	1/2003
2013/0098360	A1	4/2013	Hurmez et al.	GB	2392836	A	3/2004
2013/0116661	A1	5/2013	Coward et al.	GB	2393655	A	4/2004
2013/0150763	A1	6/2013	Mirzaei et al.	GB	2425487	A	11/2006
2013/0152945	A1	6/2013	Locke et al.	GB	2452720	A	3/2009
2013/0165887	A1	6/2013	Eric Mitchell et al.	GB	2496310	A	5/2013
2013/0172843	A1	7/2013	Kurata	JP	1961003393		2/1961
2013/0189339	A1	7/2013	Vachon	JP	S62139523	U	9/1987
2013/0261585	A1	10/2013	Lee	JP	862-275456	A	11/1987
2013/0296760	A1	11/2013	Ramminger et al.	JP	2005205120	A	8/2005
2013/0304007	A1	11/2013	Toth	JP	2007254515	A	10/2007
2013/0330486	A1	12/2013	Shields	JP	4129536	B2	8/2008
2014/0039423	A1	2/2014	Riesinger	JP	2012050274	A	3/2012
2014/0039424	A1	2/2014	Locke	SG	71559		4/2002
2014/0058309	A1	2/2014	Addison et al.	WO	80/02182	A1	10/1980
2014/0107561	A1	4/2014	Dorian et al.	WO	87/04626	A1	8/1987
2014/0107562	A1	4/2014	Dorian et al.	WO	8707164	A1	12/1987
2014/0141197	A1	5/2014	Hill et al.	WO	90/010424	A1	9/1990
2014/0155849	A1	6/2014	Heaton et al.	WO	93/009727	A1	5/1993
2014/0163491	A1	6/2014	Schuessler et al.	WO	94/20041	A1	9/1994
2014/0171851	A1	6/2014	Addison	WO	96/05873	A1	2/1996
2014/0178564	A1	6/2014	Patel	WO	9622753	A1	8/1996
2014/0249495	A1	9/2014	Mumby et al.	WO	97/18007	A1	5/1997
2014/0309574	A1	10/2014	Cotton	WO	99/13793	A1	3/1999
2014/0336557	A1	11/2014	Durdag et al.	WO	99/65542	A1	12/1999
2014/0350494	A1	11/2014	Hartwell et al.	WO	01/36188	A1	5/2001
2014/0352073	A1	12/2014	Goenka	WO	01/60296	A1	8/2001
2015/0030848	A1	1/2015	Goubard	WO	0168021	A1	9/2001
2015/0045752	A1	2/2015	Grillitsch et al.	WO	0185248	A1	11/2001
2015/0057625	A1	2/2015	Coulthard	WO	0185249	A1	11/2001
2015/0080788	A1	3/2015	Blott et al.	WO	0190465	A2	11/2001
2015/0080815	A1	3/2015	Chakravarthy et al.	WO	0243743	A1	6/2002
2015/0094646	A1	4/2015	Vinton	WO	02062403	A1	8/2002
2015/0119830	A1	4/2015	Luckemeyer et al.	WO	03-018098	A2	3/2003
2015/0119833	A1	4/2015	Coulthard et al.	WO	03045294	A1	6/2003
2015/0119834	A1	4/2015	Locke et al.	WO	03045492	A1	6/2003
2015/0141941	A1	5/2015	Allen et al.	WO	03053484	A1	7/2003
2015/0190286	A1	7/2015	Allen et al.	WO	2004/024197	A1	3/2004
2015/0209200	A1	7/2015	Fouillet et al.	WO	2004112852	A1	12/2004
2015/0217077	A1	8/2015	Scampoli et al.	WO	2005002483	A2	1/2005
2015/0290041	A1	10/2015	Richard	WO	2005062896	A2	7/2005
2016/0000610	A1	1/2016	Riesinger	WO	2005105176	A1	11/2005
2016/0067107	A1	3/2016	Cotton	WO	2005123170	A1	12/2005
2016/0144084	A1	5/2016	Collinson et al.	WO	2007022097	A2	2/2007
				WO	2007070269	A1	6/2007
				WO	2007085396	A1	8/2007
				WO	2007087811	A1	8/2007
				WO	2007113597	A2	10/2007
				WO	2007/133618	A2	11/2007
AU	755496	B2	12/2002	WO	2008026117	A1	3/2008
AU	2009200608	A1	10/2009	WO	2008041926	A1	4/2008
CA	2005436	A1	6/1990	WO	2008048527	A2	4/2008
CN	87101823	A	8/1988	WO	2008054312	A1	5/2008
DE	26 40 413	A1	3/1978	WO	2008/082444	A2	7/2008
DE	43 06 478	A1	9/1994	WO	2008/100440	A1	8/2008
DE	29 504 378	U1	9/1995	WO	2008104609	A1	9/2008
DE	202014100383	U1	2/2015	WO	2008/131895	A1	11/2008
EP	0059049	A1	9/1982	WO	2008149107	A1	12/2008
EP	0097517	A1	1/1984	WO	2009002260	A1	12/2008
EP	0100148	A1	2/1984	WO	2009/066106	A1	5/2009
EP	0117632	A2	9/1984	WO	2009066105	A1	5/2009
EP	0161865	A2	11/1985	WO	2009081134	A1	7/2009
EP	0251810	A2	1/1988	WO	2009089016	A1	7/2009
EP	0275353	A2	7/1988				
EP	0358302	A2	3/1990				
				FOREIGN PATENT DOCUMENTS			

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	2009124100	A1	10/2009
WO	2009126103	A1	10/2009
WO	2010011148	A1	1/2010
WO	2010016791	A1	2/2010
WO	2010032728	A1	3/2010
WO	2010056977	A2	5/2010
WO	2010129299	A2	11/2010
WO	2011008497	A2	1/2011
WO	2011/049562	A1	4/2011
WO	2011043786	A1	4/2011
WO	2011115908	A1	9/2011
WO	2011121127	A1	10/2011
WO	2011130570	A1	10/2011
WO	2011135284	A1	11/2011
WO	2011162862	A1	12/2011
WO	2012/112204	A1	8/2012
WO	2012104584	A1	8/2012
WO	2012140378	A1	10/2012
WO	2012143665	A1	10/2012
WO	2013009239	A1	1/2013
WO	2013066426	A2	5/2013
WO	2013090810	A1	6/2013
WO	2014/022400	A1	2/2014
WO	2014039557	A1	3/2014
WO	2014078518	A1	5/2014
WO	2014097069	A1	6/2014
WO	2014113253	A1	7/2014
WO	2014/143488	A1	9/2014
WO	2014140608	A1	9/2014
WO	2015065615	A1	5/2015
WO	2015130471	A1	9/2015
WO	2017048866	A1	3/2017

OTHER PUBLICATIONS

Susan Mendez-Eatmen, RN; "When wounds Won't Heal" RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24.

James H. Blackburn II, MD et al.: Negative-Pressure Dressings as a Bolster for Skin Grafts; *Annals of Plastic Surgery*, vol. 40, No. 5, May 1998, pp. 453-457; Lippincott Williams & Wilkins, Inc., Philadelphia, PA, USA.

John Masters; "Reliable, Inexpensive and Simple Suction Dressings"; Letter to the Editor, *British Journal of Plastic Surgery*, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK.

S.E. Greer, et al. "The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin" *British Journal of Plastic Surgery* (2000), 53, pp. 484-487.

George V. Letsou, MD., et al; "Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch"; *Journal of Cardiovascular Surgery*, 31, 1990, pp. 634-639.

Orringer, Jay, et al; "Management of Wounds in Patients with Complex Enterocutaneous Fistulas"; *Surgery, Gynecology & Obstetrics*, Jul. 1987, vol. 165, pp. 79-80.

International Search Report for PCT International Application PCT/GB95/01983; Nov. 23, 1995.

PCT International Search Report for PCT International Application PCT/GB98/02713; Jan. 8, 1999.

PCT Written Opinion; PCT International Application PCT/GB98/02713; Jun. 8, 1999.

PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; Jan. 15, 1998 & Apr. 29, 1997.

PCT Written Opinion, PCT International Application PCT/GB96/02802; Sep. 3, 1997.

Dattilo, Philip P., Jr., et al; "Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture"; *Journal of Textile and Apparel, Technology and Management*, vol. 2, Issue 2, Spring 2002, pp. 1-5.

Kostyuchenok, B.M., et al; "Vacuum Treatment in the Surgical Management of Purulent Wounds"; *Vestnik Khirurgi*, Sep. 1986, pp. 18-21 and 6 page English translation thereof.

Davydov, Yu. A., et al; "Vacuum Therapy in the Treatment of Purulent Lactation Mastitis"; *Vestnik Khirurgi*, May 14, 1986, pp. 66-70, and 9 page English translation thereof.

Yusupov, Yu.N., et al; "Active Wound Drainage", *Vestnik Khirurgi*, vol. 138, Issue 4, 1987, and 7 page English translation thereof.

Davydov, Yu.A., et al; "Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds"; *Vestnik Khirurgi*, Oct. 1988, pp. 48-52, and 8 page English translation thereof.

Davydov, Yu.A., et al; "Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy"; *Vestnik Khirurgi*, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof.

Chariker, Mark E., M.D., et al; "Effective Management of incisional and cutaneous fistulae with closed suction wound drainage"; *Contemporary Surgery*, vol. 34, Jun. 1989, pp. 59-63.

Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24.

Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2.

Svedman, P.: "Irrigation Treatment of Leg Ulcers", *The Lancet*, Sep. 3, 1983, pp. 532-534.

Chinn, Steven D. et al.: "Closed Wound Suction Drainage", *The Journal of Foot Surgery*, vol. 24, No. 1, 1985, pp. 76-81.

Arnljots, Björn et al.: "Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers", *Scand J. Plast Reconstr. Surg.*, No. 19, 1985, pp. 211-213.

Svedman, P.: "A Dressing Allowing Continuous Treatment of a Biosurface", *IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation*, vol. 7, 1979, p. 221.

Svedman, P. et al: "A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous of Intermittent Irrigation", *Annals of Plastic Surgery*, vol. 17, No. 2, Aug. 1986, pp. 125-133.

N.A. Bagautdinov, "Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues," *Current Problems in Modern Clinical Surgery: Interdepartmental Collection*, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986); pp. 94-96 (copy and certified translation).

K.F. Jeter, T.E. Tittle, and M. Chariker, "Managing Draining Wounds and Fistulae: New and Established Methods," *Chronic Wound Care*, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246.

G. Živadinovi?, V. ?uki?, Ž. Maksimovi?, ?. Radak, and P. Peška, "Vacuum Therapy in the Treatment of Peripheral Blood Vessels," *Timok Medical Journal* 11 (1986), pp. 161-164 (copy and certified translation).

F.E. Johnson, "An Improved Technique for Skin Graft Placement Using a Suction Drain," *Surgery, Gynecology, and Obstetrics* 159 (1984), pp. 584-585.

A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (copy and certified translation).

M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, "The 'Sandwich Technique' in the Management of the Open Abdomen," *British Journal of Surgery* 73 (1986), pp. 369-370.

D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, *Archives of Surgery* 105 (1972) pp. 511-513.

M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, "Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation," *Annals of Plastic Surgery* 38 (1997), pp. 553-562 (Morykwas I).

C.E. Tennants, "The Use of Hyperemia in the Postoperative Treatment of Lesions of the Extremities and Thorax," *Journal of the American Medical Association* 64 (1915), pp. 1548-1549.

Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211.

V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract,

(56)

References Cited

OTHER PUBLICATIONS

editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”).
 V.A. Kuznetsov & N.a. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”).

V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”).

V.A.C. ® Therapy Clinical Guidelines: A Reference Source for Clinicians; Jul. 2007.

Office Action for related U.S. Appl. No. 14/965,675, dated Dec. 12, 2018.

Office Action for related U.S. Appl. No. 14/619,714, dated Dec. 3, 2018.

Office Action for related U.S. Appl. No. 14/630,290, dated Jan. 11, 2019.

Office Action for related U.S. Appl. No. 15/265,718, dated Feb. 7, 2019.

Extended European Search Report for related application 18193559.4, mailed Dec. 17, 2018.

Office Action for related U.S. Appl. No. 14/080,348, dated Apr. 12, 2019.

Japanese Notice of Rejection for related application 2016-570333, dated Feb. 26, 2019.

Office Action for related U.S. Appl. No. 15/410,991, dated May 2, 2019.

Office Action for related U.S. Appl. No. 15/314,426, dated Aug. 29, 2019.

Office Action for related U.S. Appl. No. 15/600,451, dated Nov. 27, 2019.

Australian Office Action for related application 2018278874, dated Feb. 12, 2020.

Office Action for related U.S. Appl. No. 14/630,290, dated Apr. 30, 2020.

Office Action for related U.S. Appl. No. 15/793,044, dated May 13, 2020.

EP Informal Search Report for related application 19186600.3.

Office Action for related U.S. Appl. No. 15/884,198, dated May 19, 2020.

Office Action for related U.S. Appl. No. 16/007,060, dated Aug. 18, 2020.

Office Action for related U.S. Appl. No. 15/937,485, dated Aug. 4, 2020.

Office Action for related U.S. Appl. No. 15/793,044, dated Sep. 24, 2020.

Extended European Search Report for related application 20185730.7, dated Oct. 9, 2020.

Advisory Action for related U.S. Appl. No. 15/793,044, dated Dec. 9, 2020.

Japanese Office Action for related application 2019-235427, dated Jan. 5, 2021.

Office Action for related U.S. Appl. No. 16/151,005, dated Apr. 13, 2021.

Office Action for related U.S. Appl. No. 16/287,862, dated Nov. 2, 2021.

Office Action for related U.S. Appl. No. 16/577,535, dated Mar. 15, 2022.

Office Action for related U.S. Appl. No. 16/513,481, dated Mar. 30, 2022.

Office Action for related U.S. Appl. No. 16/528,441, dated May 9, 2022.

Extended European Search Report for related application 21209807.3, dated Jun. 1, 2022.

Office Action for related U.S. Appl. No. 17/009,328, dated Oct. 14, 2022.

Office Action for related U.S. Appl. No. 16/733,023, dated Feb. 9, 2023.

Office Action for related U.S. Appl. No. 17/122,855, dated Feb. 7, 2023.

Office Action for related U.S. Appl. No. 16/513,481, dated Feb. 22, 2023.

Office Action for related U.S. Appl. No. 17/151,489, dated Feb. 23, 2023.

Office Action for related U.S. Appl. No. 16/746,425, dated Aug. 17, 2023.

Office Action for related U.S. Appl. No. 16/733,023, dated Sep. 7, 2023.

Office Action for related U.S. Appl. No. 17/480,930, dated Oct. 3, 2023.

International Search Report and Written Opinion date mailed Oct. 19, 2010; PCT International Application No. PCT/US2009/036217. NPD 1000 Negative Pressure Wound Therapy System, Kalypto Medical, pp. 1-4, dated Sep. 2008.

International Search Report and Written Opinion for PCT/GB2008/003075 mailed Mar. 11, 2010.

International Search Report and Written Opinion for PCT/GB2008/004216 dated Jul. 2, 2009.

International Search Report and Written Opinion for PCT/GB2012/000099 dated May 2, 2012.

EP Examination Report for corresponding application 12705381.7, dated May 22, 2014.

International Search Report and Written Opinion for PCT/US2012/069893 dated Apr. 8, 2013.

International Search Report and Written Opinion for PCT/US2013/070070 dated Jan. 29, 2014.

International Search Report and Written Opinion for PCT/US2014/016320 dated Apr. 15, 2014.

International Search Report and Written Opinion for PCT/US2014/056566 dated Dec. 5, 2014.

International Search Report and Written Opinion for PCT/US2014/056508 dated Dec. 9, 2014.

International Search Report and Written Opinion for PCT/US2014/056524 dated Dec. 11, 2014.

International Search Report and Written Opinion for PCT/US2014/056594 dated Dec. 2, 2014.

International Search Report and Written opinion for PCT Application PCT/US2009/036222, mailed Dec. 15, 2009.

International Search Report and Written Opinion for PCT/US2014/061251 date mailed May 8, 2015.

International Search Report and Written Opinion for PCT/IB2013/060862 date mailed Jun. 26, 2014.

International Search Report and Written Opinion for PCT/US2015/015493 mailed May 4, 2015.

Extended European Search Report for corresponding Application No. 15194949.2, mailed Mar. 11, 2016.

European Search Report for corresponding EPSN 15157408.4 published on Sep. 30, 2015.

International Search Report and Written Opinion for PCT/US2015/034289 mailed Aug. 21, 2015.

International Search Report and Written Opinion for PCT/US2015/065135 mailed Apr. 4, 2016.

International Search Report and Written Opinion for PCT/GB2012/050822 mailed Aug. 8, 2012.

International Search Report and Written Opinion for PCT/US2015/029037 mailed Sep. 4, 2015.

International Search Report and Written Opinion for PCT International Application No. PCT/US2011/028344, mailed Jun. 1, 2011.

European Search Report for EP 11714148.1, dated May 2, 2014.

European Search Report for corresponding Application No. 15192606.0 mailed Feb. 24, 2016.

International Search Report and Written Opinion for corresponding PCT/US2014/048081 mailed Nov. 14, 2014.

International Search Report and Written Opinion for corresponding PCT/US2014/010704 mailed Mar. 25, 2014.

European Examination Report dated Jun. 29, 2016, corresponding to EP Application No. 16173614.5.

International Search Report and Written Opinion for corresponding PCT application PCT/US2016/051768 issued Dec. 15, 2016.

European Search Report for corresponding EP Application 171572787 issued on Jun. 6, 2017.

(56)

References Cited

OTHER PUBLICATIONS

International Search Report and Written Opinion for corresponding application PCT/US2016/031397, mailed Aug. 8, 2016.
European Search Report for corresponding application 17167872.5, mailed Aug. 14, 2017.
M. Waring et al., "Cell attachment to adhesive dressing: qualitative and quantitative analysis", Wounds, UK, (2008), vol. 4, No. 3, pp. 35-47.
R. White, "Evidence for atraumatic soft silicone wound dressing use". Wound, UK (2005), vol. 3, pp. 104-108, Mepilex Border docs, (2001).
European Search Report for corresponding application 17183683.6, mailed Sep. 18, 2017.
European Search Report for corresponding application 17164033.7, mailed Oct. 13, 2017.
Extended European Search Report for corresponding application 17191970.7, mailed Oct. 26, 2017.
Japanese office action for related application 2015-547246, mailed Sep. 5, 2017.
Office Action for related U.S. Appl. No. 13/982,650, mailed Dec. 14, 2017.
Australian Office Action for related application 2013344686, mailed Nov. 28, 2017.
Office Action for related U.S. Appl. No. 14/517,521, mailed Dec. 12, 2017.

Office Action for related U.S. Appl. No. 14/490,898, mailed Jan. 4, 2018.
International Search Report and Written Opinion for related application PCT/US2017/058209, mailed Jan. 10, 2018.
Office Action for related U.S. Appl. No. 14/965,675, mailed Jan. 31, 2018.
International Search Report and Written Opinion for related application PCT/US2016/047351, mailed Nov. 2, 2016.
Extended European Search Report for related application 17177013.4, mailed Mar. 19, 2018.
Extended European Search Report for related application 16793298.7, mailed Mar. 27, 2018.
Office Action for related U.S. Appl. No. 14/965,675, dated Aug. 9, 2018.
Office Action for related U.S. Appl. No. 15/307,472, dated Oct. 18, 2018.
Office Action for related U.S. Appl. No. 17/226,976, dated Dec. 21, 2023.
European Examination Report for related application 21158749.8, dated Feb. 8, 2024.
Office Action for related U.S. Appl. No. 18/375,313, dated Jun. 5, 2024.
Chinese Office Action for related application 2020108367584, dated Aug. 2, 2024.

* cited by examiner




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7






FIG. 9






FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20

**DRESSING AND METHOD FOR APPLYING
REDUCED PRESSURE TO AND
COLLECTING AND STORING FLUID FROM
A TISSUE SITE**

CROSS-REFERENCE TO RELATED
APPLICATIONS

This application is a continuation of U.S. application Ser. No. 15/944,639, filed Apr. 3, 2018, which is a continuation of U.S. application Ser. No. 14/703,667, filed May 4, 2015 which is a divisional of U.S. application Ser. No. 13/709,255, filed Dec. 10, 2012, now U.S. Pat. No. 9,050,209, which is a continuation of U.S. application Ser. No. 12/398,904, filed Mar. 5, 2009, now U.S. Pat. No. 8,372,050, which claims the benefit of U.S. Provisional Application No. 61/034,013, filed Mar. 5, 2008, and U.S. Provisional Application No. 61/049,028, filed Apr. 30, 2008. Each of the applications referenced above are hereby incorporated by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates generally to tissue treatment systems and in particular to dressings for distributing reduced pressure to and collecting and storing fluid from a tissue site.

2. Description of Related Art

Clinical studies and practice have shown that providing a reduced pressure in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds. This treatment (frequently referred to in the medical community as “negative pressure wound therapy,” “reduced pressure therapy,” or “vacuum therapy”) provides a number of benefits, including faster healing and increased formulation of granulation tissue. Typically, reduced pressure is applied to tissue through a porous pad or other manifold device. The porous pad contains cells or pores that are capable of distributing reduced pressure to the tissue and channeling fluids that are drawn from the tissue. The porous pad may be incorporated into a dressing having other components that facilitate treatment.

SUMMARY

The problems presented by existing collection canisters are solved by the systems and methods of the illustrative embodiments described herein. In one illustrative embodiment, a reduced pressure dressing for applying reduced pressure treatment to a tissue site is provided. The reduced pressure dressing includes an interface layer adapted to be positioned at the tissue site. An absorbent layer is in fluid communication with the interface layer to absorb liquid from at least one of the interface layer and the tissue site. A pump is in fluid communication with the absorbent layer to deliver a reduced pressure to the tissue site. A cover is positioned over the pump, the absorbent layer, and the interface layer to maintain the reduced pressure at the tissue site, and a liquid-air separator is positioned between the absorbent layer and the pump to inhibit liquid from entering the pump.

In another illustrative embodiment, a reduced pressure dressing for applying reduced pressure treatment to a tissue site includes an interface layer adapted to be positioned at the tissue site. An absorbent layer is in fluid communication with the interface layer to absorb liquid from at least one of the interface layer and the tissue site. A pump is in fluid communication with the absorbent layer to deliver a reduced pressure to the tissue site. A diverter layer is positioned between the absorbent layer and the pump, and the diverter layer includes a plurality of apertures to transmit the reduced pressure from the pump to the absorbent layer. A cover is positioned over the pump, the diverter layer, the absorbent layer, and the interface layer to maintain the reduced pressure at the tissue site. A liquid-air separator is positioned between the diverter layer and the pump to inhibit liquid from entering the pump.

In another illustrative embodiment, a reduced pressure dressing for applying reduced pressure treatment to a tissue site is provided. The reduced pressure dressing includes an interface layer adapted to be positioned at the tissue site and an absorbent layer in fluid communication with the interface layer to absorb liquid from at least one of the interface layer and the tissue site. A diverter layer is adjacent the absorbent layer, and the diverter layer is formed from a substantially gas-impermeable material. The diverter layer includes a plurality of apertures in fluid communication with the absorbent layer to increase an amount of time that the absorbent layer is able to distribute reduced pressure. A pump is in fluid communication with the plurality of apertures of the diverter layer to deliver a reduced pressure to the tissue site. A cover is positioned over the pump, the diverter layer, the absorbent layer, and the interface layer to maintain the reduced pressure at the tissue site. A liquid-air separator is positioned between the diverter layer and the pump to inhibit liquid from entering the pump.

In still another illustrative embodiment, a reduced pressure dressing for applying reduced pressure treatment to a tissue site is provided. The reduced pressure dressing includes an interface layer adapted to be positioned at the tissue site. A first manifold layer is in fluid communication with the interface layer, and an absorbent layer is in fluid communication with the first manifold layer to absorb liquid from at least one of the first manifold layer, the interface layer, and the tissue site. A diverter layer is formed from a substantially gas-impermeable material, and the diverter layer includes a plurality of spaced apertures in fluid communication with the absorbent layer. A second manifold layer is in fluid communication with the diverter layer. A pump is in fluid communication with the second manifold layer to deliver a reduced pressure to the tissue site. A cover is positioned over the pump, the second manifold layer, the diverter layer, the absorbent layer, the first manifold layer, and the interface layer to maintain the reduced pressure at the tissue site. A liquid-air separator is positioned between the second manifold and the pump to inhibit liquid from entering the pump.

In yet another illustrative embodiment, a method for collecting liquid in a dressing positioned at a tissue site includes generating a reduced pressure using a pump positioned within the dressing. A liquid is absorbed from the tissue site and is stored in the dressing. The liquid is prevented from entering the pump.

In another illustrative embodiment, a reduced pressure dressing adapted to distribute a reduced pressure to a tissue site includes an interface layer adapted to be positioned at the tissue site. An absorbent layer is in fluid communication with the interface layer to absorb liquid from at least one of

3

the interface layer and the tissue site. A pump is in fluid communication with the absorbent layer to deliver the reduced pressure to the tissue site, a diverter layer is positioned between the absorbent layer and the pump. The diverter layer is formed from a substantially gas-impermeable material and includes a surface area smaller than a surface area of the absorbent layer such that flow is directed around at least one perimeter edge of the diverter layer. A cover is positioned over the diverter layer to maintain the reduced pressure at the tissue site.

In still another illustrative embodiment, a reduced pressure dressing adapted to distribute a reduced pressure to a tissue site is provided. The dressing includes an interface layer adapted to be positioned at the tissue site. An absorbent layer is in fluid communication with the interface layer to absorb liquid from at least one of the interface layer and the tissue site. A pump is in fluid communication with the absorbent layer to deliver the reduced pressure to the tissue site, and a diverter layer is positioned between the absorbent layer and the pump. The diverter layer is formed from a substantially gas-permeable, liquid impermeable material. A cover is positioned over the diverter layer to maintain the reduced pressure at the tissue site.

Other objects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates a perspective view of a reduced pressure treatment system according to an illustrative embodiment, the reduced pressure treatment system having a dressing positioned at a tissue site;

FIG. 2 depicts a cross-sectional front view of the dressing of FIG. 1 taken at 2-2;

FIG. 3 illustrates an exploded perspective view of the dressing of FIG. 1;

FIG. 4 depicts a top view of a diverter layer the dressing of FIG. 3;

FIG. 5 illustrates a top view of a diverter layer according to an illustrative embodiment;

FIG. 6 depicts a top view of the diverter layer of FIG. 5; FIG. 7 illustrates a perspective view of a diverter layer according to an illustrative embodiment;

FIG. 8 depicts a top view of the diverter layer of FIG. 7;

FIG. 9 illustrates a top view of a diverter layer according to an illustrative embodiment;

FIG. 10 depicts an exploded perspective view of a reduced pressure dressing according to an illustrative embodiment;

FIG. 11 illustrates a top view of a drape for use with a reduced pressure dressing according to an illustrative embodiment;

FIG. 12 depicts a cross-sectional front view of the drape of FIG. 11;

FIG. 13 illustrates a cross-sectional front view of a drape for use with a reduced pressure dressing according to an illustrative embodiment;

FIG. 14 depicts a top view of a tissue interface layer for use with a reduced pressure dressing according to an illustrative embodiment;

FIG. 15 illustrates a top view of a tissue interface layer for use with a reduced pressure dressing according to an illustrative embodiment;

4

FIG. 16 depicts a graph showing vacuum pressure versus time for a reduced pressure treatment system applying reduced pressure to a tissue site according to an illustrative embodiment;

FIG. 17 illustrates an exploded perspective view of a reduced pressure treatment dressing according to an illustrative embodiment;

FIG. 18 depicts a perspective view of a reduced pressure treatment system according to an illustrative embodiment, the reduced pressure treatment system having a dressing with an integrated pump positioned at a tissue site;

FIG. 19 illustrates a cross-sectional front view of the dressing and pump of FIG. 18 taken at 19-19; and

FIG. 20 depicts an exploded perspective view of the dressing and pump of FIG. 18.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

In the following detailed description of several illustrative embodiments, reference is made to the accompanying drawings that form a part hereof, and in which is shown by way of illustration specific preferred embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the illustrative embodiments are defined only by the appended claims.

The term “reduced pressure” as used herein generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure associated with tissue at the tissue site. Although the terms “vacuum” and “negative pressure” may be used to describe the pressure applied to the tissue site, the actual pressure reduction applied to the tissue site may be significantly less than the pressure reduction normally associated with a complete vacuum. Reduced pressure may initially generate fluid flow in the area of the tissue site. As the hydrostatic pressure around the tissue site approaches the desired reduced pressure, the flow may subside, and the reduced pressure is then maintained. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Similarly, references to increases in reduced pressure typically refer to a decrease in absolute pressure, while decreases in reduced pressure typically refer to an increase in absolute pressure.

The term “tissue site” as used herein refers to a wound or defect located on or within any tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. The term “tissue site” may further refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it is desired to add or promote the growth of additional tissue. For example, reduced pressure tissue treatment may be used in certain tissue areas to grow additional tissue that may be harvested and transplanted to another tissue location.

Reduced pressure treatment systems are often applied to large, highly exudating wounds present on patients undergoing acute or chronic care, as well as other severe wounds that are not readily susceptible to healing without application of reduced pressure. Low-severity wounds that are smaller in volume and produce less exudate have generally been treated using advanced dressings instead of reduced pressure treatment. These advanced dressings, however, are not adapted for use with reduced pressure and are subject to several drawbacks when used in conjunction with reduced pressure. For example, these current dressings may fail to make optimal use of fluid storage capacity in the dressing. Additionally, existing dressings are not configured to adequately transmit reduced pressure, especially as the dressings begin to absorb and store fluid.

Currently, the use of reduced pressure treatment is not considered a viable or affordable option for low-severity wounds due to the manpower required to monitor and change system components, the requirement for trained medical personnel overseeing treatment, and the cost of treatment. For example, the complexity of current reduced pressure treatment systems limits the ability of a person with little or no specialized knowledge from administering such treatment to oneself or others. The size of current reduced pressure treatment systems also impairs the mobility of both the treatment system and the person to whom the treatment is being applied. For example, current reduced pressure treatment systems require the use of a separate canister that stores exudate or other liquid from the tissue site. Current reduced pressure treatment systems are also typically non-disposable after each treatment, and require electrical components or other powered devices in order to apply the reduced pressure used in treatment.

Reduced Pressure Dressing

Referring to FIG. 1, a reduced pressure treatment system 100 according to an illustrative embodiment includes a reduced pressure dressing 104 positioned at a tissue site 108 of a patient. The reduced pressure dressing 104 is fluidly connected to a reduced pressure source 110 by a conduit 112. The conduit 112 may fluidly communicate with the reduced pressure dressing 104 through a tubing adapter 116. In the embodiment illustrated in FIG. 1, the reduced pressure source 110 is a manually-actuated pump such as, for example, a compressible bellows pump. In another implementation, the reduced pressure source 110 may be a reduced pressure or vacuum pump driven by a motor. In another embodiment, the reduced pressure source 110 may be a powered micropump such as, for example, a piezoelectric disc pump, or alternatively a peristaltic pump. In still another embodiment, the reduced pressure source 110 may be a wall suction port such as are available in hospitals and other medical facilities.

The reduced pressure source 110 may be housed within a reduced pressure treatment unit, which may also contain sensors, processing units, alarm indicators, memory, databases, software, display units, and user interfaces that further facilitate the application of reduced pressure treatment to the tissue site 108. In one example, a sensor or switch (not shown) may be disposed at or near the reduced pressure source 110 to determine a source pressure generated by the reduced pressure source 110. The sensor may communicate with a processing unit that monitors and controls the reduced pressure that is delivered by the reduced pressure source 110. Delivery of reduced pressure to the reduced pressure dressing 104 and tissue site 108 encourages new tissue growth by maintaining drainage of exudate from the tissue

site, increasing blood flow to tissues surrounding the tissue site, and creating microstrain at the tissue site.

Referring to FIGS. 2 and 3, the reduced pressure dressing 104 includes an interface layer 220 adapted to be positioned at the tissue site 108, and a seal layer 222 to seal the reduced pressure dressing 104 around the tissue site 108. A first manifold layer 224 is in fluid communication with the interface layer 220 to distribute the reduced pressure to the interface layer 220 and the tissue site 108. An absorbent layer 228 is positioned in fluid communication with the first manifold layer 224 to absorb liquid from at least one of the first manifold layer 224, the interface layer 220, and the tissue site 108. A diverter layer 232 is positioned adjacent the absorbent layer 228. A second manifold layer 236 is positioned in fluid communication with the diverter layer 232, and a liquid-air separator 240 is positioned adjacent the second manifold layer 236. A cover 244, or drape, is positioned adjacent the liquid-air separator 240.

The interface layer 220 of the reduced pressure dressing 104 is adapted to contact the tissue site 108. The interface layer 220 may be partially or fully in contact with the tissue site 108 being treated by the reduced pressure dressing 104. When the tissue site 108 is a wound, the interface layer 220 may partially or fully fill the wound.

The interface layer 220 may be any size, shape, or thickness depending on a variety of factors, such as the type of treatment being implemented or the nature and size of the tissue site 108. For example, the size and shape of the interface layer 220 may be customized by a user to cover a particular portion of the tissue site 108, or to fill or partially fill the tissue site 108. Although the interface layer 220 illustrated in FIG. 3 has a square shape, the interface layer 220 may be shaped as a circle, oval, polygon, an irregular shape, or any other shape.

In one illustrative embodiment, the interface layer 220 is a foam material that functions as a manifold to provide reduced pressure to the tissue site 108 when the interface layer 220 is in contact with or near the tissue site 108. The foam material may be either hydrophobic or hydrophilic. In one non-limiting example, the interface layer 220 is an open-cell, reticulated polyurethane foam such as GranuFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Texas.

In the example in which the interface layer 220 is made from a hydrophilic material, the interface layer 220 also functions to wick fluid away from the tissue site 108, while continuing to provide reduced pressure to the tissue site 108 as a manifold. The wicking properties of the interface layer 220 draw fluid away from the tissue site 108 by capillary flow or other wicking mechanisms. An example of a hydrophilic foam is a polyvinyl alcohol, open-cell foam such as V.A.C. WhiteFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Texas. Other hydrophilic foams may include those made from polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.

The interface layer 220 may further promote granulation at the tissue site 108 when a reduced pressure is applied through the reduced pressure dressing 104. For example, any or all of the surfaces of the interface layer 220 may have an uneven, coarse, or jagged profile that causes microstrains and stresses at the tissue site 108 when reduced pressure is applied through the interface layer 220. These microstrains and stresses have been shown to increase new tissue growth.

In one embodiment, the interface layer 220 may be constructed from bioresorbable materials that do not have to

be removed from a patient's body following use of the reduced pressure dressing 104. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include without limitation polycarbonates, polyfumarates, and caprolactones. The interface layer 220 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with the interface layer 220 to promote cell-growth. A scaffold is a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth. Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials.

The seal layer 222 of the reduced pressure dressing 104 includes an aperture or opening 231 and provides a seal around the tissue site 108. The seal layer 222 may serve as a gasket around a portion of the tissue site 108 to prevent reduced pressure applied to the reduced pressure dressing 104 from leaking out of the reduced pressure dressing 104. The seal layer 222 may also be used to secure the interface layer 220 at the tissue site 108. If the cover 244 is applied to the tissue surrounding the tissue site 108 with wrinkles in the cover 244, then the seal layer 222 assists in maintaining in the wrinkled areas of the cover 244.

The seal layer 222 may be any size and thickness capable of providing a seal around the tissue site 108. In the example of FIG. 2, a length, L2, and a width, W2, of the seal layer 222 are greater than a length, L1, and a width, W1, of the interface layer 220, respectively. Thus, portions of the seal layer 222 extend past the edges of the interface layer 220. These portions may contact the tissue surrounding the tissue site 108 directly, thereby providing a seal around the tissue site 108 and the interface layer 220.

While the seal layer 222 illustrated in FIG. 3 has a square shape, the seal layer 222 may also have any other shape that provides a seal around the tissue site 108 or the interface layer 220. Non-limiting examples of other shapes include a circle, oval, any polygonal shape, an irregular shape, or a shape that is customized to contour to the tissue surrounding the tissue site 108 or the interface layer 220.

The seal layer 222 may be made from any material that is capable of sealing around the treated portion of the tissue site 108. In one illustrative embodiment, the seal layer 222 may include or be made from a hydrogel. The seal layer 222 may also include either or both of a hydrocolloid or silicon.

Although the seal layer 222 is shown as being disposed adjacent to the interface layer 220, the seal layer 222 may be positioned adjacent or between any of the layers in the reduced pressure dressing 104. Additional details regarding the positioning of the seal layer 222 are discussed in more detail below with reference to FIG. 2.

The reduced pressure dressing 104 also includes a first manifold layer 224 for distributing the reduced pressure to and withdrawing liquid, such as exudate, from the interface layer 220. When the seal layer 222 is positioned adjacent the interface layer 220, liquid may be withdrawn from the tissue site 108 through the aperture 231. As a reduced pressure is applied to the reduced pressure dressing 104, the liquid is wicked from the tissue site 108 by the interface layer 220 and drawn through the aperture 231 of the seal layer 222 by the first manifold layer 224.

In one embodiment, a length, L3, and a width, W3, of the aperture 231 is less than the length, L1, and the width, W1, of the interface layer 220. However, in other embodiments,

particularly in those embodiments in which one or more other layers are disposed between the seal layer 222 and the interface layer 220, the length, L3, and the width, W3, of the aperture 231 may be equal to or larger than the length, L1, and the width, W1, of the interface layer 220. While the aperture 231 illustrated in FIG. 3 has a square shape, the aperture 231 may instead have any other shape that allows the seal layer 222 to provide a seal while facilitating the passage of liquid from the tissue site 108.

The first manifold layer 224 may have any size, shape, or thickness. For example, the size and shape of the first manifold layer 224 may be customized to provide differing levels of utilization of the absorbent layer 228. The size and shape of the first manifold layer 224 may also be customized based on the size and shape of other components in the reduced pressure dressing 104, such as the size and shape of the interface layer 220, the seal layer 222, the aperture 231, the absorbent layer 228, or other layers in the reduced pressure dressing 104.

The first manifold layer 224 is a biocompatible, porous material that is capable of distributing reduced pressure to the tissue site 108. The first manifold layer 224 may be made from foam, gauze, felted mat, or any other material suited to a particular biological application. The first manifold layer 224 includes a plurality of flow channels or pathways to facilitate distribution of reduced pressure or fluids to or from the tissue site 108. In one embodiment, the first manifold layer 224 is a porous foam and includes a plurality of interconnected cells or pores that act as flow channels. The porous foam may be a polyurethane, open-cell, reticulated foam such as GranuFoam® dressing. If an open-cell foam is used, the porosity may be about 400 to 600 microns or any other porosity capable of adequately manifolded reduced pressure. The flow channels allow fluid communication throughout the portion of first manifold layer 224 having open cells. The cells and flow channels may be uniform in shape and size, or may include patterned or random variations in shape and size. Variations in the shape and size of the cells of the first manifold layer 224 result in variations in the flow channels, and such characteristics may be used to alter the flow characteristics of fluid through first manifold layer 224. The first manifold layer 224 may be either hydrophobic or hydrophilic. In one embodiment, the first manifold layer 224 may be made from the same material as the interface layer 220.

In one embodiment, the first manifold layer 224 may be made from a material that expands upon contact with a liquid, such as exudate from the tissue site 108, such that the first manifold layer 224 will fill a wound site or otherwise contact the tissue site 108. In this embodiment, the first manifold layer 224 may enable the interface layer 220 to be removed, thereby simplifying the construction and reducing the thickness or profile of the reduced pressure dressing 104.

The absorbent layer 228 of the reduced pressure dressing 104 is disposed adjacent the first manifold layer 224 for receiving and absorbing the liquids distributed by the first manifold layer 224. The first manifold layer 224 facilitates the migration of liquid from the tissue site 108 radially outward toward the edges of the first manifold layer 224, as indicated generally by the multi-directional arrows 239 so that the liquid is distributed more uniformly across the absorbent layer 228. The absorbent layer 228 will retain more liquid if the liquid is more uniformly distributed across the surface of the absorbent layer 228.

As used herein, a "surface area" of a layer refers to an area measurement of the layer as may be determined in a plane that is positioned adjacent to or in contact with other layers.

In the example illustrated in FIG. 3, the surface areas of the first manifold layer 224 and the absorbent layer 228 are determined by multiplying the lengths and widths of the respective layers, the lengths and widths being measured in a plane substantially parallel to the plane containing the length, L3, and the width, W3, of the aperture 231.

A surface area (defined as $L3 \times W3$) of the aperture 231 in FIG. 3 may be less than a surface area of the first manifold layer 224 and a surface area of the absorbent layer 228. If the first manifold layer 224 failed to distribute the liquid radially toward the edges of the first manifold layer 224, then the absorbent layer 228 would primarily absorb liquid in a portion of the absorbent layer 228 having a same size as the aperture 231. However, because the first manifold layer 224 is capable of radially distributing liquid from the tissue site 108 in the directions indicated by the multi-directional arrows 239, a larger surface area of the absorbent layer 228 is exposed to the liquid, and the absorbent layer 228 can store a larger volume of fluid. While the reduced pressure dressing 104 is designed primarily for use with reduced pressure, the distribution of liquid from the tissue site 108 in the directions indicated by the multi-directional arrows 239 may occur during the application of or in the absence of reduced pressure. A more complete utilization of the absorbent layer 228 may be achieved using the first manifold layer 224 even when reduced pressure is not being applied to the reduced pressure dressing 104.

The absorbent layer 228 is adapted to absorb liquid, such as exudate, from the tissue site 108 via the interface layer 220 and the first manifold layer 224 through the aperture 231 of the seal layer 222. The absorbent layer 228 is also adapted to manifold and transfer reduced pressure through those layers to the tissue site 108. The absorbent layer 228 may be made from any material capable of absorbing liquid, such as exudate from the tissue site 108. In one embodiment, the absorbent layer 228 may be made from a super absorbent fiber. The super absorbent fibers may hold onto or bond to the liquid in conjunction with a physical or chemical change to the fibers. In one non-limiting example, the super absorbent fiber may include the Super Absorbent Fiber (SAF) material from Technical Absorbents®, Ltd. The absorbent layer 228 may be a sheet or mat of fibrous material in which the fibers absorb liquid from the tissue site 108. The structure of the absorbent layer 228 that contains the fibers may be either woven or non-woven. The fibers in the absorbent layer 228 may gel upon contact with the liquid, thereby trapping the liquid. Spaces or voids between the fibers may allow a reduced pressure that is applied to the reduced pressure dressing 104 to be transferred within and through the absorbent layer 228. In one embodiment, the fiber density of fibers in the absorbent layer 228 may be approximately 1.4 grams per millimeter.

The absorbent layer 228 may have any size, shape, or thickness. If additional liquid storage capacity is desired for the reduced pressure dressing 104, then a larger or thicker absorbent layer 228 may be used. In another example, the size and thickness of the absorbent layer 228 may be reduced for space-saving, convenience, compactness, or cost considerations.

The reduced pressure dressing 104 may also include a diverter layer 232 disposed adjacent to the absorbent layer 228, a second manifold layer 236 disposed adjacent to the diverter layer 232, and a liquid-air separator 240 disposed adjacent to the second manifold layer 236. The diverter layer 232 includes a plurality of holes 247 through which reduced pressure from the reduced pressure source 110 (see FIG. 1) is applied. The reduced pressure is distributed to the diverter

layer 232 by the second manifold layer 236. The holes 247 may be arranged in a pattern for applying the reduced pressure to portions of the absorbent layer 228 to enhance the capability of the absorbent layer 228 to continue transferring the reduced pressure to the tissue site 108 as it absorbs more fluid from the tissue site 108. In the embodiment illustrated in FIG. 3, the plurality of holes 247 are positioned in a pattern around a peripheral portion of the diverter layer 232 away from the center of the diverter layer 232 such that the reduced pressure is applied to the absorbent layer 228 away from a center region of the absorbent layer 228. The diverter layer 232 acts in conjunction with the first manifold layer 224 to ensure that the absorption capabilities and absorption efficiency of the absorbent layer 228 is increased relative to an absorbent layer that is not used in conjunction with a diverter layer. By providing better distribution of liquid throughout the absorbent layer 228, the diverter layer 232 also increases an amount of time over which the absorbent layer 228 is capable of manifolded reduced pressure in the dressing 104.

The diverter layer 232 may be made from any material that enhances the reduced pressure transmission and storage capabilities of an adjacent absorbent layer. For example, the diverter layer 247 may be made from a material that is substantially impermeable to liquid and gas. Alternatively, the material from which the diverter layer 232 is made may instead have a predetermined moisture vapor transfer rate that is consistent with gas permeability. In either example, the diverter layer 232 may still include a pattern of holes for transmitting a greater volume of liquid or gas than that permitted by the gas-permeable material of which the diverter layer 232 is constructed. It should be noted, however, that permeability of the diverter layer 232 to gas but not liquid may result in increased transmission of reduced pressure through the dressing while still directing liquid flow around or near the perimeter of the diverter layer 232.

In the embodiment illustrated in FIG. 3, the reduced pressure creates fluid flow through the holes 247. The fluid flow through holes 247 directs liquid pulled into the absorbent layer 228 away from a center region of the absorbent layer 228. The presence of holes 247 and the fluid flow through the holes 247 may also lessen the absorption rate of liquid in the center region of the absorbent layer 228 and allow the absorbent layer 228 to absorb liquid over a larger area. Thus, the gas and liquid are not limited only to traveling through the center of the absorbent layer 228 or other layers that may be disposed closer to the tissue site 108 than the diverter layer 232. Because both the gas and liquid are directed radially outward toward the edges of the absorbent layer 228, a greater portion of absorbent material is exposed to the liquid from the tissue site 108, and a larger portion of the absorbent layer 228 may therefore be used to store or trap a greater volume of the liquid.

The fuller utilization of the absorbent layer 228 allows for the reduced pressure dressing 104 to be used for a longer period of time without having to dispose the reduced pressure dressing 104. The need to distribute gas and liquid toward the edges of the absorbent layer 228 may be even greater in the presence of reduced pressure due to the speed at which liquid may flow away from the tissue site 108 through the reduced pressure dressing 104.

The diverter layer 232 has primarily been described as assisting in diverting reduced pressure or fluid flow to a perimeter region of the absorbent layer 228. Alternatively, the diverter layer 232 could instead be configured to assist in diverting reduced pressure to any particular region, i.e. a target region, of the absorbent layer 228 to encourage liquid

absorption within the target region. For example, if a tissue site and a dressing were of a configuration that naturally resulted in liquid collection in a perimeter region of a particular absorbent layer, then a diverter layer could be configured to encourage liquid collection within the center region of the absorbent layer. In this particular example, the center region would be the target region.

Referring still to FIGS. 2 and 3, the second manifold layer 236 distributes the reduced pressure more uniformly across the surface of the diverter layer 232. The second manifold layer 236 may be made from any material capable of distributing or manifolding fluid. In one example, the second manifold layer 236 may be made from a same or similar material as the first manifold layer 224. In this example, the second manifold layer 236 may include a plurality of interconnected cells that form a porous foam. The second manifold layer 236 may also collect liquid, such as exudate, from the tissue site 108 that is not absorbed by the absorbent layer 228. The second manifold layer 236 may have any size, shape, or thickness.

In one embodiment of the reduced pressure dressing 104, the liquid-air separator 240 may be a hydrophobic filter that inhibits or prevents passage of liquids through the liquid-air separator 240. Alternatively, the liquid-air separator 240 may be a gravity-based barrier system, or a device that includes a hydrophilic surface to encourage condensation or other separation of liquid from a fluid stream when the fluid stream passes over the surface. Other examples of liquid-air separators 240 may include sintered metals, sintered nylons, or any other material or device that is capable of separating liquid from a fluid stream, or that is otherwise capable of inhibiting or preventing the passage of liquid while allowing the passage of gases.

By restraining or preventing the flow of liquid, the liquid-air separator 240 prevents liquid from reaching the tubing adapter 116 or conduit 112 (see FIG. 1). By preventing liquid from reaching the conduit 112, the liquid-air separator 240 also prevents the liquid from reaching the reduced pressure source 110.

The liquid-air separator 240 may prevent the passage of reduced pressure to the tissue site 108 when the liquid-air separator 240 becomes saturated, clogged, blocked, and/or wetted with liquid from the tissue site 108. The liquid-air separator 240 may also prevent the passage of reduced pressure to the tissue site 108 when a layer that abuts the liquid-air separator 240 becomes saturated with liquid. For example, if the absorbent layer 228 abutted the liquid-air separator 240 in a particular embodiment, the saturation of the absorbent layer 228 with liquid may cause the liquid-air separator 240 to prevent the passage of reduced pressure. The presence of the diverter layer 232 between the liquid-air separator 240 and the absorbent layer 228 prolongs the period of time before the liquid-air separator 240 blocks the passage of reduced pressure.

The liquid-air separator 240 may have any size, shape, or thickness. In one example, the liquid-air separator 240 may be smaller than other layers in the reduced pressure dressing 104 due to cost considerations. The liquid-air separator 240 may also be wider than the tubing adapter 116 and an aperture 260 in the cover 244 so that liquid from the tissue site 108 cannot reach the tubing adapter 116 or the aperture 260.

The cover 244 of the reduced pressure dressing 104 covers at least a portion of the reduced pressure dressing 104. In one embodiment, the cover 244 may fully cover the multiple layers of the reduced pressure dressing 104. In this embodiment, the cover 244 may secure or assist in securing

the reduced pressure dressing 104 to the tissue site 108 and in maintaining a seal around the tissue site 108. In this respect, both the cover 244 and the seal layer 222 may work together to create a seal around the tissue site 108. The cover 244 may also provide a protective barrier for the reduced pressure dressing 104 and the tissue site 108.

In the embodiment illustrated in FIGS. 2 and 3, the cover 244 may cover and secure components and layers between the cover 244 and the diverter layer 232. In this embodiment, the cover 244 may be secured either adhesively or otherwise to the diverter layer 232. The diverter layer 232, which may be made from a similar material as the cover 244, is then secured to either or both of the seal layer 222 and the tissue at or near the tissue site 108. The diverter layer 232 in this embodiment secures and seals the components and layers beneath the diverter layer 232 at the tissue site 108.

In one embodiment, the cover 244 may be an adhesive drape. The adhesion of the cover 244 may be due to the nature of the material with which the cover 244 is made, or may be due to an adhesive layer disposed on a surface of the cover 244. Any portion of the cover 244 may include adhesive. For example, an entire tissue facing side of the cover 244 may include adhesive. When provided with adhesive, the cover 244 may adhere to at least a portion of the tubing adapter 116, the tissue surrounding the tissue site 108, or any layer or component of the reduced pressure dressing 104. In another embodiment, only the peripheral portions of the tissue facing side of the cover 244 may include adhesive. In this particular case, the adhesive-covered peripheral portions may be adapted to adhere to any of the diverter layer 232, the seal layer 222, and the tissue surrounding the tissue site 108.

In still another embodiment, the cover 244 may be designed such that the cover 244 will not adhere to wet surfaces, but will adhere to dry surfaces. Thus, when applying the cover 244, the cover 244 will not stick to moistened gloves or hands, thereby permitting easier handling of the cover 244 until the cover 244 is placed on a dry tissue site, such as a dry periwound area. The cover 244 may be any size, shape, or thickness. In one example, the cover 244 may be larger than any layer or components of the reduced pressure dressing 104. In another example, the size of the seal layer 222 may be larger than the size of the cover 244.

Reduced pressure may be applied to the plurality of layers of the reduced pressure dressing 104 via the aperture 260 in the cover 244. In the example of FIGS. 2 and 3, the aperture 260 is shown to be centrally located on the cover 244. However, the aperture 260 may be located anywhere on the cover 244, including a peripheral portion of the cover 244 that is adjacent to an edge of cover 244. Although the aperture 260 is shown to be circular, the aperture 260 may have any shape. In one example, the shape of the aperture is adapted to contour to one or more portions of the tubing adapter 116.

The tubing adapter 116 provides an interface between conduit 112 and the reduced pressure dressing 104. In particular, the tubing adapter 116 fluidly communicates with the conduit 112 such that the conduit 112 transfers reduced pressure to the reduced pressure dressing 104 and the tissue site 108 via the tubing adapter 116.

Referring to FIGS. 1 and 2, the tubing adapter 116 may be a conventional connector pad that is adapted to abut or be partially disposed within the aperture 260. Alternatively, the tubing adapter 116 may have a low profile dome shape, or the tubing adapter 116 may be any other shape. The low profile of the tubing adapter 116 may help to keep the reduced pressure dressing 104 compact and convenient for

use by a user. The tubing adapter **116** includes a flange **266**, which is disposed around the periphery of the tubing adapter **116**. In the embodiment illustrated in FIGS. **2** and **3**, the tissue facing side of the cover **244** near the aperture **260** may be adapted to adhere to the flange **266** such that the tubing adapter **116** is secured to at least one layer or component of the reduced pressure dressing **104**.

Although not shown in FIGS. **2** and **3**, in one embodiment the reduced pressure dressing **104** includes an odor filter. The odor filter retains or prevents odor from exiting the reduced pressure dressing **104**. The odor filter may be a carbon odor filter, which may include charcoal. In one example, the odor filter is a charcoal cloth. The odor filter may be positioned anywhere in the reduced pressure dressing **104** such as, for example, between the cover **244** and the liquid-air separator **240**.

The reduced pressure dressing **104** may further include an indicator (not shown) to alert a user when the reduced pressure dressing **104** has reached a full liquid storage capacity and needs to be removed from the tissue site **108**. In one embodiment, the indicator may be a chemical or other substance that is capable of changing visual appearance or some other characteristic in the presence of moisture. For example, an indicator may be placed in one of the layers between the cover **244** and the absorbent layer **228** such that the indicator undergoes a visible color change when liquid has fully saturated the absorbent layer and is pulled through the absorbent layer into contact with the indicator. In one embodiment, the indicator may be a part of the liquid-air separator **240**. The indicator may instead be a part of a separate indicator layer that is positioned anywhere in the dressing to signal the presence of moisture in a particular area. The indicator may cooperate with another layer of the dressing that is transparent to allow a user to view the location at which the indicator is positioned.

Although the cover **244**, the liquid-air separator **240**, the manifolds **224** and **236**, the diverter layer **232**, the absorbent layer **228**, the seal layer **222**, and the interface layer **220** have substantially square shapes in FIG. **3**, each of these components, as well as other layers disclosed herein with respect to other embodiments, may have any shape as required to provide adequate reduced pressure therapy to the tissue site **108**. For example, these components and layers may be polygonal, rectangular, circular, ovalar, an irregular shape, a customized shape, or any other shape.

While the various layers of the reduced pressure dressing **104** have been described as being “adjacent” to other layers, the term “adjacent” may refer to the layers being immediately adjacent, or alternatively that the layers may be positioned with other intervening layers in between. The term “layer” generally refers to portions or regions of the dressing that have different material properties or functions than other portions or regions of the dressing (i.e. other layers). The term “layer” is not meant to be spatially limiting however. The properties and functions associated with a particular layer may be combined with the properties and functions of another layer such that a single layer having multiple and different properties and functions is created. More specifically, for example, two or more layers may be physically or chemically bonded or combined to create a single layer without affecting the original material properties or functions of the original components. Conversely, a particular layer of the dressings described herein may be broken into two or more layers that each have similar properties or functions.

Referring more specifically to FIG. **2**, the specific arrangement of the multiple layers of the reduced pressure

dressing **104** is described in more detail. A tissue facing side **316** of the interface layer **220** is shown to be abutting the tissue site **108**. In one example, the tissue facing side **316** of the interface layer **220** has an uneven surface that promotes granulation of the tissue site **108** when reduced pressure is applied through the interface layer **220**. The uneven surface include a fibrous surface that causes microstresses and strains on the tissue site **108**.

The seal layer **222** may be disposed anywhere between the cover **244** and interface layer **220**, including between the absorbent layer **228** and interface layer **220**. In the example of FIG. **2**, the seal layer **222** is disposed between the first manifold layer **224** and the interface layer **220** such that a portion of a tissue facing side **327** of the seal layer **222** abuts the interface layer **220**. In particular, the tissue facing side of an inner edge of the seal layer **222** that forms the aperture **231** abuts the interface layer **220**.

The seal layer **222** also includes overhanging portions **329**, which extend past the edges of the interface layer **220**. The overhanging portions **329** may be adapted to adhere or otherwise contact the tissue site **108** such that a seal is created at a portion of the tissue site **108**. For example, the overhanging portion **329** may adhere or otherwise contact a periwound area surrounding a wound site such that a seal is created at the wound site.

The first manifold layer **224** may also be disposed anywhere in the reduced pressure dressing **104**. In one example, the first manifold layer **224** is disposed between the interface layer **220** and the absorbent layer **228**. In the non-limiting example of FIG. **3**, the first manifold layer **224** is disposed between the seal layer **222** and the absorbent layer **228**. In particular, a portion of a tissue facing side **336** of the first manifold layer **224** abuts the aperture **231** of the seal layer **222**. In this example, a drape facing side **337** of the first manifold layer **224** abuts the absorbent layer **228**.

In the embodiment illustrated in FIG. **2**, the absorbent layer **228** is shown to be disposed between the diverter layer **232** and the first manifold layer **224**. A tissue facing side **342** of the absorbent layer **228** abuts the first manifold layer **224**. A drape facing side **343** of the absorbent layer **228** abuts the diverter layer **232**. In one example, the diverter layer **232** may be disposed between the absorbent layer **228** and the cover **244**. A tissue facing side **347** of the diverter layer **232** abuts the absorbent layer **228**. A drape facing side **348** of the diverter layer **232** abuts the second manifold layer **236**.

The second manifold layer **236** may be disposed between the absorbent layer **228** and the cover **244**, or between the diverter layer **232** and the cover **244**. In FIG. **2**, the second manifold layer **236** is disposed between the liquid-air separator **240** and the diverter layer **232**. A tissue facing side **352** of the second manifold layer **236** abuts the diverter layer **232**. A drape facing side **353** of the second manifold layer **236** abuts the liquid-air separator **240**.

The liquid-air separator **240** may be disposed between the absorbent layer **228** and the cover **244**, or between the second manifold layer **236** and the cover **244**. In FIG. **2**, a tissue facing side **356** of the liquid-air separator **240** abuts the second manifold layer **236**. A portion of a drape facing side **357** of the liquid-air separator **240** abuts the tubing adapter **116**.

A tissue facing side **351** of the tubing adapter **116** abuts the liquid-air separator **240**. Also, a portion of the tubing adapter **116** is shown to protrude from an aperture in the cover **244**. The flange **266** of the tubing adapter **116** is sandwiched between the cover **244** and the liquid-air separator **240** such that the cover **244** secures the tubing adapter **116** to at least one of the plurality of layers, such as the

liquid-air separator **240**. As illustrated in FIG. 2, the liquid-air separator **240** may be wider than the aperture **260** in the cover **244**, and the second manifold layer **236** may be wider than the liquid-air separator **240**.

The cover **244** may cover all or a part of the reduced pressure dressing **104**. For example, the ends of the cover **244** may terminate at a location on the overhanging portions **329** of the seal layer **222**. As indicated by the broken lines **380**, the cover **244** may also terminate at a location on the tissue site **108**.

Referring to FIGS. 4, the diverter layer **232** includes a pattern of holes, or other apertures for applying the reduced pressure to portions of the absorbent layer **228** (not shown). The holes have different diameters. More specifically, the diameter of holes **450** are larger than the diameter of holes **247**. In operation, the diverter layer **232** channels more reduced pressure to the corners of a square absorbent layer **228** to further enhance the transmission capability of the absorbent layer **228** because the corners are the last portion of the absorbent layer **228** to fill with liquid as liquid diffuses radially outward from the center of the absorbent layer **228**.

Referring to FIGS. 5 and 6, a diverter layer **545** according to an illustrative embodiment may be made from any material that expands on contact with a liquid. For example, the diverter layer **545** may be made from a hydrogel. The diverter layer **545** may also include a hydrocolloid, silicon, or silicone material. The diverter layer **545** includes holes **547**, or other apertures. The length of each of the arrows extending from each of the holes **547** represents the relative amount of flow or reduced pressure allowed through the holes. In FIG. 5, an equal amount of flow or reduced pressure is transferred through each of the holes **547**.

In some reduced pressure applications, the tissue may produce more exudate at an area away from the center of the dressing. In these cases, a greater amount of liquid may pass through a portion of the holes **547** that are positioned over the main point of exudation. In the example of FIG. 6, the main point of exudation occurs nearer to holes **648**. Thus, the holes **648** are shown to be smaller, swelling, or substantially closed off due to contact with liquid from the tissue site. The restriction of the holes **648** causes a preferential flow through the remaining holes **547**, thereby equalizing flow across an adjacent absorbent layer in the dressing. In particular, the holes **547** of diverter layer **545** as shown in FIG. 6 transmit a greater amount of reduced pressure than the holes **648**. By equalizing flow and reduced pressure in such a manner, an absorbent layer, such as absorbent layer **228** in FIGS. 2 and 3, may be more fully utilized no matter the location of the main point of exudation at the tissue site, or the pattern with which the liquid is absorbed by the absorbent layer.

Referring to FIGS. 7 and 8, a diverter layer **745** according to an illustrative embodiment includes a plurality of ridges **785** protruding from a surface of the diverter layer **745** and extending radially outward from the center to a periphery of the diverter layer **745** to form or define a plurality of channels **787** therebetween. The ridges **785** may be curved and may converge at a central portion of the diverter layer **745**. The ridged face of the diverter **745** abuts an absorbent layer (not shown) so that the channels **787** are closed to form passages **887** and **888** (FIG. 8) extending radially between the center portion and periphery of the diverter layer **745**. In FIG. 8, each of the passages **887** are shown to be unobstructed, and therefore a substantially equal amount of reduced pressure freely flows through each one. However, in some reduced pressure applications, liquid from the tissue site **108** (not shown) fills and obstructs the passages **888**.

This may occur, for example, when a main point of exudation from the tissue site is located away from the center of the dressing, including the diverter layer **745**. Because a greater amount of liquid flows through the passages **888** than the passages **887**, the passages **888** fill with the liquid and become obstructed by the saturated portions of the absorbent layer **228** abutting the passages **888** as indicated by shaded portions **889**. Thus, as indicated by the arrows on the diverter layer **745**, a greater amount of reduced pressure is applied through the passages **887** than the obstructed passages **888**. The passages **887** then become a preferential path for the reduced pressure and fluid flow until all of the absorbent layer **228** adjacent the diverter layer **745** is saturated. By equalizing flow in such a manner, the absorbent layer **228** is more fully utilized regardless of the location of the main point of exudation on the tissue site, or the pattern with which the liquid is absorbed by the absorbent layer **228**.

Referring to FIG. 9, a diverter layer **945** is shown according to an illustrative embodiment. The diverter layer **945** includes a pattern of holes **947**, or other apertures around a periphery of the diverter layer **945**. However, in contrast to the diverter layer **232** of FIGS. 2 and 3, the diverter layer **945** includes a portion **931** that does not include holes **947**. The portion **931** is capable of being aligned with a tubing adapter (similar to tubing adapter **116**) that is positioned off-center. Because reduced pressure is applied to the dressing via the tubing adapter, the presence of holes directly underneath the tubing adapter, even with one or more intervening layers, may result in a larger than desired portion of the reduced pressure being applied to the holes adjacent and underneath the tubing adapter. Eliminating holes in the portion **931** of the diverter layer **945** that is adjacent and underneath the tubing adapter applies the reduced pressure through all of the remaining holes **947** to more evenly distribute the reduced pressure to the absorbent layer **228**.

While the diverter layers of FIGS. 4-9 have been illustrated and described as including substantially circular holes, the diverter layers may instead include apertures of any shape or size, including for example slots, slits, channels, perforations, or any other apertures. Alternatively, a diverter layer may be provided without apertures that instead is sized to be smaller in perimeter dimension and/or surface area than the absorbent layer. A diverter layer having a length or width less than a length or width of the absorbent layer would ensure fluid flow travels around perimeter edges of the diverter layer, thus having the same effect as placement of apertures near an edge of a larger diverter layer.

Referring to FIG. 10, a reduced pressure dressing **1000** is shown according to an illustrative embodiment. The reduced pressure dressing **1000** is similar to the reduced pressure dressing **104** of FIGS. 2 and 3. The reduced pressure dressing **1000** is not shown with the tubing adapter **116** or the cover **244** of FIGS. 2 and 3, but includes the absorbent layer **228** and the diverter layer **232**. The reduced pressure dressing **1000** further includes a heat/moisture exchange (HME) foam **1015**, which is a non-limiting example of the interface layer **220** in FIGS. 2 and 3. The HME foam **1015** may be a hydrophilic foam that wicks liquid from the tissue site **108**. The HME foam **1015** may also distribute reduced pressure to the tissue site. In one example, the tissue-facing side of the HME foam **1015** has an uneven surface such that granulation is promoted at the tissue site **108** when reduced pressure is applied through the HME foam **1015**. Each of the arrows in FIG. 10 represents the flow of either or both of gas or liquid when reduced pressure is applied to the reduced pressure dressing **1000**. The arrows illustrate how the

diverter layer **232** facilitates the distribution of gas and liquid throughout the reduced pressure dressing **1000** to more effectively utilize the absorbent layer **228**. For example, the arrows show that the presence of the diverter layer **232** causes liquid to be drawn radially outward toward the edges of the absorbent layer **228** to more fully utilize the absorbent capacity of the absorbent layer **228**.

The reduced pressure dressing **1000** also includes a second absorbent layer **1040** disposed adjacent the diverter layer **232** on a side opposite the first absorbent layer **228**, and a second HME layer **1041** disposed adjacent the opposite side of the second absorbent layer **1040**. The second HME layer **1041** may be an open-celled and/or hydrophilic foam. In one example, the HME layer **1041** is made of the same material as the HME foam **1015**. Liquid from the tissue site **108** (not shown) is absorbed and drawn into the HME foam **1015** and transferred to the absorbent layer **228**. The liquid is absorbed by the absorbent layer **228**, and is pulled through the holes **247** of the diverter layer **232**, thereby spreading the liquid and leading to higher utilization of the absorbent layer **228**. In the non-limiting example in which a hydrogel diverter layer, such as diverter layer **545** in FIG. **5**, is used in lieu of the diverter layer **232**, gel blocking can occur at the holes **247** so that liquid is forced to move around in the absorbent layer **228** and is distributed. The second absorbent layer **1040** further absorbs any liquid flowing through the diverter layer **232** while the second HME layer **1041** manifolds a reduced pressure across the second absorbent layer **1040**. In some cases, the second HME layer **1041** may be subjected to compression forces when reduced pressure is applied through the reduced pressure dressing **1000**. Despite such compression forces, the second HME layer **1041** may still contain open pressure channels that allow the second HME layer **1041** to transfer reduced pressure to other parts of the reduced pressure dressing **1000**. A filter, such as liquid-air separator **240**, may be positioned above the HME layer **1041** to restrain or prevent the liquid from leaving the reduced pressure dressing **1000**.

Referring to FIGS. **11** and **12**, a drape **1125**, or cover, is provided that may be used with a reduced pressure dressing such as, for example, reduced pressure dressing **104** of FIGS. **1-3**. The drape **1125** includes an elastic portion **1110**. The elastic portion **1110** is centrally located on the drape **1125**. The elastic portion **1110** may be made from any elastic material. Also, although FIGS. **11** and **12** do not show an aperture on the elastic portion **1110**, the elastic portion **1110** may include an aperture, such as the aperture **260** in FIG. **2**. The aperture may be located anywhere on the elastic portion **1110**. The elastic portion **1110** is bonded to a peripheral portion **1115** at a bonding area **1120**. The bond at the bonding area **1120** may be formed using any bonding technique. For example, the elastic portion **1110** may be glued or otherwise adhered to the peripheral portion **1115** at the bonding area **1120**.

The peripheral portion **1115** may be made from any material, including an elastic or a non-elastic material. In one example, the peripheral portion **1115** includes an aperture. A tissue facing side **1122** of the peripheral portion **1115** may include an adhesive so that the drape **1125** may be used to cover and secure one or more layers, such as the layers of reduced pressure dressing **104**. In another embodiment, both the elastic portion **1110** and the peripheral portion **1115** may be made from the same material and be continuous with one another so that no bond is needed between the elastic portion **1115** and the peripheral portion **1115** at the bonding area **1120**.

As illustrated in FIG. **12**, the elastic portion **1110** may expand to a plurality of positions, from an unexpanded position shown by the solid line to an expanded position **1110a** shown by the broken line. As the reduced pressure dressing with which the drape **1125** is used fills with liquid, the elastic portion **1110** moves to the expanded position **1110a**. The ability of the drape **1125** to move to the expanded position **1110a** allows for additional room in the reduced pressure dressing for the storage of liquid from the tissue site **108** (not shown).

As an alternative to a drape having an elastic portion, the drape **1125** may instead be made from an inelastic material that is capable of plastically deforming into an expanded position as fluid is collected in a dressing. The drape **1125** may instead include a combination of elastic and inelastic materials, and expansion may be based on both elastic and plastic deformation of the materials.

Referring to FIG. **13**, a drape **1325**, or cover, includes a pleated portion **1310** that is centrally located on the drape **1310**. The pleated portion **1310** may be made from an elastic or a non-elastic material. The pleated portion **1310** also includes one or more corrugations **1312**, or ridges. The corrugations may be located on any or all sides of the pleated portion **1310**. Also, although FIG. **13** shows one corrugation on each side of the pleated portion **1310**, each side of the pleated portion **1310** may include any number of corrugations, which may form a bellows-like structure. The pleated construction of the pleated portion **1310** allows the pleated portion **1310** to expand as liquid is stored in an underlying reduced pressure dressing.

The drapes **1125** and **1325** of FIGS. **11-13** are capable of expanding to accommodate fluid collection and storage in a reduced pressure dressing. It is also important to note that the drapes **1125** and **1325** are capable of maintaining reduced pressure in the dressing before, during, and after expansion.

Referring to FIGS. **14** and **15**, interface layers **1400** and **1500** are illustrated according to illustrative embodiments. The interface layers **1400** and **1500** are tearable sheets foam material that include kiss-cut perforations **1405** and **1505** that allow for the easy tearing and sizing of the interface layers **1400** and **1500** for use in a dressing, such as reduced pressure dressing **104**. In one example, when the interface layers **1400** and **1500** are kiss-cut, the cutting die penetrates through most of the thickness of the foam material, but not fully. This provides a weakened path to tear along, while still allowing the foam to maintain a shape. In FIG. **14**, the kiss-cut perforations **1405** are a series of concentric circles. A properly sized interface layer may be torn along any one of the concentric circles. In FIG. **15**, the kiss-cut perforation **1505** is a continuous spiral-like perforation. The kiss-cut perforation **1505** may be torn along this continuous perforation as needed to size the interface layer prior to use with the dressing.

The kiss-cut perforations **1405** and **1505** provide a weakened path along which the interface layer may be torn. When a portion of the interface layers **1400** and **1500** is used in a dressing, the interface layer may still have some perforations remaining. However, despite having these perforations, the interface layer is still able to maintain a desirable shape and effectively perform the functions of the interface layer described herein.

Referring to FIG. **16**, a graph **1600** that shows example characteristics of a reduced pressure dressing is shown. The graph **1600** illustrates a drop in pressure measured as a function of time at an interface layer of a reduced pressure dressing to which fluid is added at about 2 milliliters per

hour. In particular, the graph **1600** shows a pressure measured at an interface layer of a dressing that is about 8 cm 2 and includes an HME foam with a secondary Super Absorbent Fiber layer dressing mounted on a large tube during the test. The reduced pressure applied to the dressing throughout the test is a consistent 125 mmHg. As time passes and the dressing fills with fluid, the pressure eventually drops at the interface layer as the dressing is no longer able to adequately manifold reduced pressure. The graph **1600** represents characteristics of only one particular reduced pressure dressing, and other illustrative embodiments of the dressing described herein may exhibit different characteristics than those shown in the graph **1600**.

Referring to FIG. **17**, a dressing **1700** according to an illustrative embodiment includes an interface layer **1715**. In contrast to the interface layer **220** in FIG. **2**, the interface layer **1715** has a larger size relative to the other layers in the dressing. The dressing **1700** includes absorbent layer **228** above the tissue interface layer **1715**, and diverter layer **232** above the absorbent layer **228**. In contrast to the reduced pressure dressing **104**, the dressing **1700** includes another absorbent layer **1740** above the diverter layer **232**. The absorbent layer **1740** is similar to the absorbent layer **228**. The absorbent layer **1740** may be added to increase the absorbency of the dressing **1700**. The absorbent layer **1740** may also be used to catch liquid that travels past or escapes from the absorbent layer **228**.

The dressing **1700** includes second manifold layer **236** above the absorbent layer **1740**, and liquid-air separator **240** above the second manifold layer **236**. The dressing **1700** also includes a seal layer **1724** (similar to the seal layer **222** of FIG. **2**) above the liquid-air separator **240**. The seal layer **1724** has a circular aperture **1730**, although the circular aperture **1730** may be any shape. The dressing **1700** may also include a tubing adapter **1740** and cover **244**. The tubing adapter **1740** may be a low-profile dome shape or any other shape.

In one embodiment, the components of the dressing **1700** that are adapted to contact a tissue site are the tissue interface layer **1715**, the seal layer **1724**, and the cover **244**. However, the components of the dressing **1700** may be sized such that any of the components may come into contact with the tissue site.

In another illustrative embodiment, a method is provided for collecting fluid in a dressing positioned at a tissue site. The method includes applying a reduced pressure to the tissue site through the dressing, absorbing liquid from the tissue site, and storing the liquid in the dressing. The method further includes preventing the liquid from exiting the dressing. In one embodiment, the step of absorbing liquid from the tissue site is accomplished with an absorbent layer similar to the absorbent layers described herein. The method may further comprise diverting reduced pressure to a target region of the absorbent layer to increase an absorption efficiency associated with the absorbent layer. Diversion of the reduced pressure to the target region may also increase an amount of time that the absorbent layer is able to distribute reduced pressure.

The illustrative embodiments of reduced pressure dressings described herein may contain a diverter layer to ensure that even pressure distribution is maintained as an absorbent layer absorbs fluid. The diverter layer also promotes the efficient use of the absorbent material in the dressing. The illustrative embodiments may also contain a porous hydrophobic filter that prevents the dressing from allowing liquid, such as exudate, from entering a tubing and helping to ensure pressure distribution. The construction of the dress-

ing and the sequence of layers in the illustrative embodiments help to ensure the optimal absorbency of the dressing combined with the communication of reduced pressure to the tissue site.

Current wound dressings are designed to absorb liquid to maintain a moist wound environment while minimizing the risk of maceration, but are unsuited to adequately manifold reduced pressure. Current dressings that are not currently used with reduced pressure will not normally transmit pressure to a tissue site. These current dressings are designed only to absorb fluid and are routinely changed. The dressings described in the illustrative embodiments are adapted to provide therapy and more absorbent capacity both with and without reduced pressure, and may be applied to a large variety of wounds, including low-severity wounds and low-exudating wounds. The dressings described in the illustrative embodiments will allow reduced pressure tissue therapy without impacting the dressings' absorbency.

Without the diversion provided by components such as the diverter layer, liquid may be absorbed by the absorbent layer and concentrated into a restricted area around the point of exudation. This may lead to large amounts of the absorbent layer being unused. For example, when a reduced pressure source of 125 mmHg is connected to a reduced pressure dressing, the absorbent material may release some of the absorbed liquid, which will bypass the rest of the absorbent area and be drawn directly into the tube that connects the reduced pressure source to the dressing. At this point, the dressing may cease to absorb any more liquid, and as the liquid enters the tube, the dressing's ability to transmit reduced pressure to the tissue site is impaired. Furthermore, this may occur when only a fraction of the target fluid quantity has been absorbed. However, by using a diverter layer and other layers described herein, the efficiency of the absorbent layers may be increased so that the reduced pressure dressing is capable of absorbing more liquid and manifold reduced pressure for a longer period of time.

The components of the reduced pressure dressings described herein are illustrated in a non-limiting spatial configuration that may be altered depending on the implementation. Although the figures show components of the reduced pressure dressings in a particular order, the components may have any order depending on the implementation. Similarly, the inclusion or exclusion of any particular component may vary depending on the particular application.

Dressing with Integrated Pump

The reduced pressure dressings and components in FIGS. **1-17** have been described as being adapted for connection to a reduced pressure source external to the dressing. However, the reduced pressure dressings described herein are also capable of incorporating an integrated pump, i.e. a pump positioned within or between layers of the dressing, to deliver reduced pressure through the layers of the dressing to the tissue site.

Referring to FIG. **18**, a reduced pressure treatment system **1800** according to an illustrative embodiment includes a reduced pressure dressing **1804** positioned at a tissue site **1808** of a patient. The reduced pressure dressing **1804** includes a reduced pressure pump **1810** that is integrated into the reduced pressure dressing **1804**. In addition to the reduced pressure pump **1810**, other components may also be integrated into the dressing, including without limitation sensors, processing units, control units, alarm indicators, memory, databases, software. Additionally, the reduced pressure dressing **1804** may include interfaces (wireless or wired) that allow fluid communication between components

within the dressing **1804** and components that may be outside of the dressing **1804**. In one non-limiting example, the interface may be a USB port. The external components may include without limitation control units, display units, battery chargers, and user interfaces that further facilitate the application of reduced pressure treatment to the tissue site **1808**. Delivery of reduced pressure to the reduced pressure dressing **1804** and tissue site **1808** by the reduced pressure pump **1810** encourages new tissue growth by maintaining drainage of exudate from the tissue site, increasing blood flow to tissues surrounding the tissue site, and creating microstrain at the tissue site.

Referring to FIGS. **19** and **20**, the reduced pressure dressing **1804** includes an interface layer **1920** adapted to be positioned at the tissue site **1808**, and a seal layer **1922** to seal the reduced pressure dressing **1804** around the tissue site **1808**. A first manifold layer **1924** is positioned in fluid communication with the interface layer **1920** to distribute the reduced pressure to the interface layer **1920** and the tissue site **1808**. An absorbent layer **1928** is positioned in fluid communication with the first manifold layer **1924** to absorb liquid from at least one of the first manifold layer **1924**, the interface layer **1920**, and the tissue site **1808**. A diverter layer **1932** positioned adjacent the absorbent layer **1928**. A second manifold layer **1936** is positioned in fluid communication with the diverter layer **1932**, and a liquid-air separator **1940** is positioned adjacent the second manifold layer **1936**. A cover **1944**, or drape, is positioned adjacent the second liquid-air separator **1940**. An indicator and odor filter may also be positioned within the reduced pressure dressing **1804**.

The multiple layers of reduced pressure dressing **1804** are similar in shape, size, positioning, and function to the layers of any of the other reduced pressure dressings described herein. In addition to the layers of dressing **1804** listed above, the reduced pressure dressing **1804** includes a pump **1810** that may be integrated into the dressing between the liquid-air separator **1940** and the cover **1944**. The pump **1810** may be a micropump that is small and light enough such that the integrated reduced pressure dressing **1804** is able to be maintained on the tissue site **1808**. Furthermore, the size and weight of the pump **1810** should be such that the integrated reduced pressure dressing **1804** does not pull or otherwise adversely affect the tissue site **1808**. In one embodiment, the pump **1810** may be a disk pump having a piezoelectric actuator similar to that described in International Patent Application No. PCT/GB2006/001487, published as WO 2006/111775, which is hereby incorporated by reference. In an alternative embodiment, the pump **1810** may be a peristaltic pump that is used for pumping a variety of fluids. It should be understood that alternative pump technologies may be utilized and that rotary, linear, or other configurations of pumps may be utilized.

The pump **1810** may be used to create enough reduced pressure to be "therapeutic" for wound therapy. In one embodiment, the pump **1810** has sufficient flow, vacuum, and operation life characteristics to enable continuous application of reduced pressure treatment. The flow may range between about 5-1000 ml/min, the vacuum may range between about 50-200 mmHg, and continuous operating life may last greater than 20 hours. It should be understood that alternative ranges may be utilized depending on the configuration of the integrated reduced pressure dressing **1804**, size of wound, type of wound, or otherwise. In one embodiment, multiple pumps may be positioned in a single dressing to deliver increased flow rates or vacuum levels as required. Alternatively, a selection of pumps having different opera-

tional capabilities and specifications may be kept on hand by a user or medical practitioner to allow optimization of a pump and dressing combination for a particular tissue site.

The pump **1810** is disposed within the dressing to avoid conduits and external canisters for collection of wound exudate. The pump **1810** may include a valve **1950** or outlet port to release air or exhaust out of the reduced pressure dressing **1804**. If valve **1950** is used, the valve **1950** may be in fluid communication with, or may be positioned within, an aperture **1960** of the cover **1944**. Alternatively, the cover **1944** may be sealed around an outlet port of the pump **1810** such that gas from the pump **1810** is able to exhaust directly through the aperture **1960**. In the embodiment illustrated in FIGS. **18-20**, the valve or outlet port of the pump **1810** is oriented in a direction away from the hydrophobic filter to avoid adding air to the wound dressing. The air exhausts through an aperture **1960** in the cover **1944**, which may include a one-way valve. Alternatively, the air or other gas could be exhausted through a gas-permeable portion of the cover **1944** as long as the ability of the cover **1944** to maintain reduced pressure is not affected.

When a piezoelectric-driven pump is used in a dressing, the piezoelectric actuator associated with the pump may be driven at different frequencies to act as a buzzer or vibrating alert system. The alert system may be used to alert a user to an alarm condition such as the presence of a leak in the dressing, a change in reduced pressure as measured by a sensor, an indication that the dressing has absorbed a maximum capacity of liquid as may be indicated by an indicator, or an indication that one or more layer are no longer manifolded reduced pressure efficiently.

Control electronics **2024** may be utilized to control operation of the pump **1810**. The control electronics **2024** may be analog and/or digital and be configured with a regulator (not shown) to regulate speed or duty cycle at which the pump **1810** operates. Furthermore, the control electronics **2024** may be configured with a controller (not shown) that receives sense signals from sensors or switches (not shown). The sensors may be disposed throughout the integrated reduced pressure dressing **1804** to sense parameters, such as pressure, temperature, moisture, chemistry, odor, or any other parameter that may be utilized in managing and controlling the pump **1810**. In one embodiment, the control electronics **2024** include a computer processor. Alternatively, the control electronics **2024** may include a programmable gate array. Still yet, the control electronics **2024** may be formed of analog electronic components. It should be understood that the control electronics **2024** may include any form of digital and/or analog components to perform functionality as described herein.

As understood in the art, there are four basic parameters that are of concern when performing reduced pressure wound treatment, including (i) low pressure, (ii) excessive leak, (iii) level of absorbent layer, and (iv) battery state. Accordingly, the control electronics **2024** may include electronics that may be utilized to monitor each of the four basic parameters and generate an alarm signal (e.g., high-pitched beep, vibration, or light) using a speaker (not shown), vibrator (not shown), or illumination device (not shown), such as a light emitting diode (LED), to notify a medical professional, patient, or family member that a parameter is outside of a safe range. For example, if a pressure at the wound site is below a therapeutic level, a continuous tone may be generated. As another example, if the absorbent layer **1928** is saturated, then continuous beeps may be generated. Still yet, if the battery drops below a certain voltage level, then a different frequency may be generated

and/or LED may be turned on. A variety of different alarm signals may be established to notify a medical professional to take a particular action.

A battery **2026** may be utilized to provide electric power to the pump **1810** and control electronics **2024**. The battery **2026** may have any size and shape configuration and be of any material, such as polymer, to accommodate weight and size of the integrated reduced pressure dressing **1804**, as previously described. In one embodiment, the battery **2026** may be rechargeable. In another embodiment, the battery **2026** may be disposed within or outside of the integrated reduced pressure dressing **1804** and be positioned in such a manner as to allow for easy replacement or recharging. In one embodiment, the battery **2026** may be configured with a voltage level sensor (not shown) that is monitored by the control electronics **2024** for determination of a low power level. In one embodiment, the battery **2026** may be directly connected with the pump **1810**. Alternatively, the battery **2026** may be connected to the control electronics **2024** that use power from the battery **2026** to drive the pump **1810**. The control electronics **2024** may provide continuous power, modulated power, such as a pulsewidth modulated (PWM) signal, to drive the pump **1810**.

The seal layer **1922** may be adhered to or otherwise connected to the cover layer **1944** that is used to drape or otherwise cover the integrated reduced pressure dressing **1804**. The seal layer **1922** may include an aggressive or medical grade adhesive material that is strong enough to form a vacuum seal with skin around a wound of a patient. The seal layer **1922** may be a band that has an opening **2032** that is slightly larger than the geometric parameters as the hydrophobic filter **2020** or other layer so that the cover layer **2030** may contact skin around the wound site of a patient. The cover layer **2030** may be impermeable to fluids, such as air and liquids. In one embodiment, the cover layer **2030** includes a valve **2034** to enable exhaust from the pump **1810** to be discharged from the integrated reduced pressure dressing **1804**. The valve **2034** may be a one-way valve to minimize fluids from entering into the integrated reduced pressure dressing **1804** via the cover layer **2030**.

In another embodiment, the seal layer **1922** may be adhered to the diverter layer **1932** and the diverter layer **1932** adhered to the cover **1944** to create an upper dressing portion and a lower dressing portion. The upper dressing portion may include the cover **1944**, the pump **1810** and related components, the liquid-air separator **1940**, the second manifold layer **1936**, and the diverter layer **1932**. The lower dressing portion may include the absorbent layer **1928**, the first manifold layer **1924**, the seal layer **1922**, and the interface layer **1920**. In one embodiment, the reduced pressure dressing may be configured to allow replacement of the lower dressing portion once the dressing has absorbed a maximum capacity of fluid. The upper dressing portion may be reused after the lower dressing portion is replaced. This allows multiple use of the pump **1810**, while disposable portions of the dressing may be replaced. In another embodiment, the pump **1810**, control electronics **2024**, and battery **2026** may be removed from the dressing for reuse and the remaining layers of the dressing replaced. In still another embodiment, the absorbent layer **1928** only may be replaced. In yet another embodiment, the absorbent layer **1928** and the interface layer **1920** only may be replaced.

A charcoal filter **2036** may be utilized in the integrated reduced pressure dressing **1804** to reduce odors created by the wound site and dispersed from the integrated reduced pressure dressing **1804**. The charcoal filter **2036** may be disposed above a valve or other output vent from the pump

1810 to filter exhaust from the pump **1810** prior to being released from the integrated reduced pressure dressing **1804**. It should be understood that the charcoal filter **2036** may be alternatively configured and disposed above or below the pump **1810**. Still yet, rather than using a charcoal filter, charcoal may be integrated into any or all of the different layers utilized in the integrated reduced pressure dressing **1804**.

In another illustrative embodiment, a method for collecting liquid in a dressing positioned at a tissue site includes generating a reduced pressure using a pump positioned within the dressing. A liquid is absorbed from the tissue site and is stored in the dressing. The liquid is prevented from entering the pump. The method may further include maintaining the reduced pressure within the dressing and exhausting gas from the pump outside the dressing.

It should be apparent from the foregoing that an invention having significant advantages has been provided. While the invention is shown in only a few of its forms, it is not just limited but is susceptible to various changes and modifications without departing from the spirit thereof.

We claim:

1. A dressing for treating a tissue site, comprising:
 - a) an absorbent layer adapted to be positioned at the tissue site to absorb liquid from the tissue site, the absorbent layer having a perimeter region and a center region;
 - b) a pump positioned within the dressing in fluid communication with the absorbent layer to provide reduced pressure to the absorbent layer;
 - c) a diverter layer comprising a substantially gas-impermeable material adapted to be positioned in fluid communication between the absorbent layer and the pump, wherein the diverter layer includes a plurality of spaced apertures in fluid communication with the absorbent layer; and
 - d) an interface layer comprising foam adapted to be positioned between the tissue site and the absorbent layer.
2. The dressing of claim 1, further comprising a liquid-air separator positioned between the absorbent layer and the pump, wherein the liquid-air separator substantially precludes liquid from entering the pump.
3. The dressing of claim 1, wherein at least one of the apertures is configured to become smaller on contact with moisture.
4. The dressing of claim 1, wherein the diverter layer is adapted to draw the liquid away from the center region of the absorbent layer towards the perimeter region of the absorbent layer.
5. The dressing of claim 1, further comprising control electronics positioned within the dressing and operatively connected to the pump.
6. The dressing of claim 1, further comprising a seal layer configured to be positioned between the diverter layer and tissue surrounding the tissue site.
7. The dressing of claim 1, wherein the diverter layer has a perimeter dimension that is smaller than a perimeter dimension of the absorbent layer such that reduced pressure flow is directed around at least one perimeter edge of the diverter layer.
8. The dressing of claim 1, wherein the diverter layer has a surface area smaller than a surface area of the absorbent layer such that reduced pressure flow is directed around at least one perimeter edge of the diverter layer.
9. The dressing of claim 1, wherein the diverter layer has a perimeter edge positioned substantially within the perimeter region of the absorbent layer and away from the center region of the absorbent layer.

25

- 10. The dressing of claim 1, wherein the diverter layer is positioned such that reduced pressure is applied to the absorbent layer substantially through the perimeter region of the absorbent layer and away from the center region of the absorbent layer.
- 11. The dressing of claim 1, wherein the pump is a piezoelectric-driven micropump.
- 12. A system including the dressing of claim 1, further comprising:
 - a cover adapted to be positioned over the dressing to provide a fluid seal relative to the tissue site; and
 - an aperture in the cover to allow exhausting of gas from the pump.
- 13. A dressing for treating a tissue site, comprising:
 - an absorbent layer adapted to be positioned at the tissue site to absorb liquid from the tissue site, the absorbent layer having a perimeter region and a center region;
 - a pump positioned within the dressing in fluid communication with the absorbent layer to provide reduced pressure to the absorbent layer; and
 - a diverter layer comprising a substantially gas-impermeable material adapted to be positioned in fluid communication between the absorbent layer and the pump, wherein the diverter layer includes a plurality of spaced apertures in fluid communication with the absorbent layer, wherein at least one of the apertures is configured to become smaller on contact with moisture.
- 14. A dressing for treating a tissue site, comprising:
 - an absorbent layer adapted to be positioned at the tissue site to absorb liquid from the tissue site, the absorbent layer having a perimeter region and a center region;
 - a pump positioned within the dressing in fluid communication with the absorbent layer to provide reduced pressure to the absorbent layer;
 - a diverter layer comprising a substantially gas-impermeable material adapted to be positioned in fluid communication between the absorbent layer and the pump, wherein the diverter layer includes a plurality of spaced apertures in fluid communication with the absorbent layer, wherein the diverter layer has a perimeter dimension that is smaller than a perimeter dimension of the absorbent layer such that reduced pressure flow is directed around at least one perimeter edge of the diverter layer.
- 15. A dressing for treating a tissue site, comprising:
 - an absorbent layer adapted to be positioned at the tissue site to absorb liquid from the tissue site, the absorbent layer having a perimeter region and a center region;

26

- a pump positioned within the dressing in fluid communication with the absorbent layer to provide reduced pressure to the absorbent layer;
- a diverter layer comprising a substantially gas-impermeable material adapted to be positioned in fluid communication between the absorbent layer and the pump, wherein the diverter layer includes a plurality of spaced apertures in fluid communication with the absorbent layer, wherein the diverter layer has a surface area smaller than a surface area of the absorbent layer such that reduced pressure flow is directed around at least one perimeter edge of the diverter layer.
- 16. A dressing for treating a tissue site, comprising:
 - an absorbent layer adapted to be positioned at the tissue site to absorb liquid from the tissue site, the absorbent layer having a perimeter region and a center region;
 - a pump positioned within the dressing in fluid communication with the absorbent layer to provide reduced pressure to the absorbent layer; and
 - a diverter layer comprising a substantially gas-impermeable material adapted to be positioned in fluid communication between the absorbent layer and the pump, wherein the diverter layer includes a plurality of spaced apertures in fluid communication with the absorbent layer, wherein the diverter layer has a perimeter edge positioned substantially within the perimeter region of the absorbent layer and away from the center region of the absorbent layer.
- 17. A dressing for treating a tissue site, comprising:
 - an absorbent layer adapted to be positioned at the tissue site to absorb liquid from the tissue site, the absorbent layer having a perimeter region and a center region;
 - a pump positioned within the dressing in fluid communication with the absorbent layer to provide reduced pressure to the absorbent layer; and
 - a diverter layer comprising a substantially gas-impermeable material adapted to be positioned in fluid communication between the absorbent layer and the pump, wherein the diverter layer includes a plurality of spaced apertures in fluid communication with the absorbent layer, wherein the diverter layer is positioned such that reduced pressure is applied to the absorbent layer substantially through the perimeter region of the absorbent layer and away from the center region of the absorbent layer.

* * * * *